The Development of a Small Molecule Transcriptional Activation Domain. by Brennan, Brian B.
 










A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Chemistry) 

















 Associate Professor Anna K. Mapp, Chair 
 Professor Mark M. Banaszak Holl 
 Professor Carol A. Fierke  























 I would like to start by thanking all of those who made impacts on my 
professional development before I began at the University of Michigan.  Fr. Sweeney 
S.J., Dr. Tribble, and Dr. Graham were truly inspirational as teachers and their passion 
for science will not be soon forgotten.  Dr. Mota de Freitas was an excellent mentor as an 
undergraduate researcher and gave me tremendous guidance throughout my time at 
Loyola University. 
 My research at the University of Michigan has been extremely collaborative over 
the years and there are numerous people to thank.  I worked closest with Aaron Minter, 
Steve Rowe, and Sara Buhrlage.  You have all been tremendous colleagues and friends 
and I could not have gotten this far without you.  Amelia, Marcelle, Alex, Zikiya, Bin, 
Jen, and Garrette: you were all here at the start and made my time in graduate school a 
great experience.  I also want to thank the rest of the Mapp lab for all the support 
throughout the years. 
 I would like to thank the members of my committee: Dr. Fierke, Dr. Banaszak 
Holl, and Dr Iniguez.  Your thought provoking questions and insight have been 
invaluable.  Additionally I would like to thank Dr. Ansari at the University of Wisconsin 
Madison and Dr. Kodadek at the University of Texas Southwestern for allowing me to 
carry out research in their labs while I was at Michigan, it proved incredible useful as 
witnessed by the work in this thesis.  Most of all, I would like to thank Anna.  You have 
 iii 
been a tremendous role model throughout my time in graduate school.  I can not thank 
you enough for all that you have done for me while I have been in your lab.  You have 
been a tremendous mentor and shaped the way I think about science.  I only hope that I 
have a fraction of the success you have had as I begin my own faculty career. 
 Miguel, Big Hört, Jeffrey, Dan, and Tom:  I’ll miss our trips to Ashley’s and 
Dominick’s (to discuss science of course).  Jen Furchak: thanks for keeping me motivated 
as we applied for faculty positions.  I could not have done it without you.  Now if we can 
just find jobs at the same school…  Most of all though Jen thanks for introducing me to 
my wife: Sarah.  Sarah, you are the most supportive, loving, and caring person I have 
ever met.  Meeting you was the best thing that happened to me in graduate school and I 
look forward to spending the rest of our lives together. 
 Lastly, I would like to thank my parents and siblings.  Mom, Dad, John, Jenny, 
Gayle, and Liz:  Your constant support for all my endeavors will never be forgotten.  
 iv 
Table of Contents 
 
Acknowledgements         ii  
 
List of Figures          vi  
 
List of Abbreviations         ix 
 
Abstract          xiii 
 
 
Chapter I: Current Picture of Transcriptional Activators   1 
 A. Significance        1 
 B. Modularity of Transcriptional Activators    2 
 C.  Transcription and Disease      3 
 D.  Transcriptional Activators      5 
 E.  Regulation of Activator Interactions     7 
 F.  Activation Domain Replacement     8 
G. Small Peptidic Activation Domains     11 
H. Non-Peptidic Transcriptional Activators    15 
I. References        20 
 
Chapter II: Features Affecting Activator Potency    24 
 
 A.  Background        24  
 B. Beyond Binding Affinity      25 
 C.  An Unusually Potent Peptidic Activation Domain   30 
 D. Binding Experiments       34 
E. Identification of the XLY Binding Site    38 
F. Dynamics of Binding       40 
 G. Model of P201 Function      42 
H. Masking Interactions and Potency     43 
 I. Experimental Details       44 
 J. References        49 
 
Chapter III: A Small Molecule Transcriptional Activation Domain  52 
 
A. Background        52 
B. Isoxazolidine Scaffold      53 
C. Testing the Isoxazolidine Activation Domains   56 
 v 
D. Results of Initial Compounds      60 
E. Conclusions from Initial Studies     62 
F. Stereochemical Promiscuity in Artificial     63 
 Transcriptional Activators  
G. Experimental Details       67 
H. References        71 
 
Chapter IV: Small Molecule Activation in Living Cells    74 
 and Insights into their Cellular Mechanism of Action 
 
A. Background        74 
B. Cellular Activity in Saccharomyces cerevisiae   75 
C. Activity in HeLa Cells      78 
D. A Fully Synthetic Activator ATF     83 
E. Insights into Cellular Mechanism of the Isoxazolidine ADs  87 
F. Experimental Details       92 
G. References        96 
 
Chapter V: Future Directions       98 
 
A. Other Isoxazolidine ADs      99 
B. Cross-linking studies       101 
C. Variation in the DBD       102 
D. Activation of Transcription in vivo     102 
E. References        103 
 
 vi 




Figure I-1: Activators bind to DNA and recruit chromatin modifying   2 
  enzymes (CME) and the RNA polymerase holoenzyme to  
  a specific gene in order to up- regulate transcription. 
Figure I-2: The DNA binding domain (DBD) of an activator (blue)  
  determines the gene to be modulated while the activation   3 
  domain (AD) (red) determines potency. 
Figure I-3: Over-expression of REST, a transcriptional repressor, is   5 
 often observed in medulloblastoma.  REST expression  
 inhibits neuronal differentiation genes through the  
 recruitment of a host of co-repressor proteins. 
Figure I-4: Acidic activation domains are composed of interspersed   6 
 polar (red) and hydrophobic (green) residues. 
Figure I-5: The structure of the GCN4 DBD bound to its requisite DNA 9  
 target. 
Figure I-6: Triplex forming oligonucleotides take advantage of Hoogsteen 10  
 base pairs in order to specifically interact with double  
 stranded DNA.   
Figure I-7: Pyrrole-imidazole polyamides are capable of binding to   10 
 each of the four DNA base pair combination through the  
 asymmetric hydrogen bond donors and acceptors presented. 
Figure I-8: Amino acid sequence of two minimal activation modules   13 
 (VP1 and ATF14) and a sequence designed to form an  
 amphipathic helix (AH) with charged residues in red, polar in  
 green, and hydrophobic in blue. 
Figure I-9: Sequences of KBP 1.66 and KBP 2.20, the peptides   14 
 discovered through phage display against the KIX domain,  
 as well as the sequence of c-Myb, an endogenous activator  
 which targets the KIX domain. 
Figure I-10: The rigid isoxazolidine scaffold is capable of displaying   16 
 varied functionality which loosely mimics common residues  
 of endogenous activators. 
Figure I-11: Wrenchnolol (left) and KBPo2 (right) activate transcription  18 
 when localized to DNA. 






Figure II-1: Mediator, shown in this electron micrograph, is composed   26 
 of a head (H) and middle (M) regions which contact RNA  
 Polymerase II directly as well as a tail (T) region which is  
 targeted by transcriptional activators. 
Figure II-2: Libraries used in the Med15 screen.     27 
Figure II-3: Med15 Ligands #17 and #28 activate transcription when   28 
 fused to the DBD of the bacterial protein LexA in a yeast  
 strain bearing LexA binding sites upstream of a lacZ reporter  
 gene. 
Figure II-4: Dissociation constants for each of the ADs and their ability  29 
 to upregulate transcription. 
Figure II-5: NMR structure of the Galdd with helix 3 and Loop 1 indicated. 31 
Figure II-6: A series of β-galactosidase assays carried out by our   33 
 collaborators. 
Figure II-7: Residues 93-100 of Gal4 are necessary for P201 function.  34 
Figure II-8: Binding affinities of XLY for Med15, Gal4dd, Gal4dd-P201,   35 
 and Med15P. 
Figure II-9: The hydrophobic Med15 ligand does not interact with the   36 
 Gal4DD. 
Figure II-10: Electrophoretic mobility shift assays demonstrating    38 
 interactions between DNA bound Gal4 (1-100) and mutants  
 of Med15. 
Figure II-11: A LexA-P201 chimera only activates transcription when   39 
 the entire Gal4dd is also present. 
Figure II-12: Alanine scanning was used to uncover important residues   40 
 for activation mediated by P201. 
Figure II-13: Fluorescence polarization was used to determine the   41 
 dissociation rates of XLY for Gal4dd and Med15. 
Figure II-14: Transient exposure of P201 leads to its remarkable activity   43 




Figure III-1: Nutlin-3 was discovered through a screen of molecules   54 
 which could disrupt the MDM2•p53 interaction. 
Figure III-2: Initial targeted isoxazolidines contained functionality often  55 
 observed in endogenous ADs. 
Figure III-3: Synthetic strategy used to prepare isoxazolidines.   56 
Figure III-4: A diagram demonstrating the method of localizing an   57 
 activation domain to DNA in a “two-hybrid” type manner. 
Figure III-5: Radioactive in vitro transcription assay.    58 
Figure III-6: Molecular beacons are an RNA or DNA oligonucleotide capable  59 
 of forming a hairpin labeled with a fluorophore (green circle)  
 and a quencher (black circle) at the 5’ and 3’ ends.    
 viii 
Figure III-7: Titration of complementary oligonucleotide with the   60 
 molecular beacon resulted in a linear dose dependent  
 increase in fluorescent signal. 
Figure III-8: Results from in vitro transcription assays.    61 
Figure III-9: Activation by the isoxazolidine is dependent on    62 
 localization to DNA. 
Figure III-10: The L and D versions of ATF29 were coupled to FK506   64 
 in order to localize them to DNA and test for activation. 
Figure III-11: Compounds used for positional “mutagenesis” study.  65 





Figure IV-1: A wrenchnolol polyamide conjugate activates transcription   75 
 in a cell-free system. 
Figure IV-2: Activation of transcription by III-4 in a yeast cell-based assay.    77 
Figure IV-3: Method of localizing the isoxazolidines to DNA in the   78 
 mammalian cell assay. 
Figure IV-4: OxDex conjugated isoxazolidines tested in the mammalian   79 
 cell assay. 
Figure IV-5: Results from the luciferase assay in HeLa cell culture.  80 
Figure IV-6: Activation by IV-1 is inhibited by the addition of IV-4.  81 
Figure IV-7: No activation is observed with the amphipathic    82 
 isoxazolidine unless it is coupled to the OxDex DNA  
 localization moiety. 
Figure IV-8: KIX binding peptoid KBPo2.      82 
Figure IV-9: The EC50 of IV-1 is 36 nM.      83 
Figure IV-10: Conjugate of polyamide (ImPy7) with the amphipathic   85 
 isoxazolidine.      
Figure IV-11: The completely synthetic activator ATF IV-5 activates   86 
 transcription in HeLa cells. 
Figure IV-12: Cross interference experiments between IV-6 and various   88 
 amphipathic ADs. 
Figure IV-13: Inhibition of basal transcription was not observed with the   89 
 addition of IV-6. 
Figure IV-14: Activation of transcription by VP2 in HeLa cells is    91 
 inhibited by the addition of IV-6.   
 
Chapter V           
 
Figure V-1: Cellular activity of derivatives of the amphipathic    100 
 isoxazolidines. 
Figure V-2: A proposed isoxazolidine with a cross-linking agent   101 
 attached to N3 in order to determine cellular targets. 
 ix 
List of Abbreviations 
 
A  alanine 
AD  activation domain 
AdML  adenovirus major-late promoter 
AEEA  8-amino-3,6-dioxaoctanoic acid 
AH  amphipathic helix 
ATCC  American Type Culture Collection 
ATF  artificial transcription factor 
ATF14  artificial transcription factor-14 
ATF29  artificial transcription factor-29 
BL21(DE3) protease deficient Escherichia coli cell line with T7 RNA polymerase 
bp  base pair 
BSA  bovine serum albumin 
BGG  bovine gamma-globulin 
C  cysteine 
cAMP  3’, 5’-cyclic adenosine monophosphate 
CBP  CREB-binding protein 
CDK8  cyclin-dependent kinase-8 
CH3CN acetonitrile 
CME  chromatin modifying enzymes 
CMV  cytomegalovirus 
c-Myb  c-myeloblastosis oncogene 
CREB  cAMP response element-binding protein 
D  aspartic acid 
Da  dalton 
DBD  DNA binding domain 
DD  dimerization domain 
DMEM Dulbecco’s modified Eagle’s medium 
DMF  N, N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
E  glutamic acid 
eDHFR E. coli dihydrofolate reductase 
EDTA  ethylenediamine tetraacetic acid 
ELISA  enzyme-linked immunosorbant assay 
EMSA  electrophoretic mobility shift assay 
ESI-MS electrospray ionization-mass spectroscopy 
F  phenylalanine 
FBS  fetal bovine serum 
 x 
FITC  fluorescein isothiocyanate 
FKBP  FK506 binding protein 
Fmoc  9-fluorenylmethoxy carbonyl   
g  gram 
G  glycine 
Gal4dd  Gal4 dimerization domain 
GST  glutathione-S-transferase 
h  hour 
H  histidine 
HBTU  2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium    
  hexafluorophosphate 
HCl  hydrochloric acid 
HeLa  Henrietta Lacks cervical cancer cell line 
HEPES N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
hGR  human glucocortocoid receptor 
HIV  human immunodeficiency virus 
HOBt  N-hydroxybenzotriazole 
HPLC  high-performance liquid chromatography 
HTH  helix-turn-helix 
Hsp90  heat shock protein 90 
I  isoleucine 
IC50  inhibitory concentration 50% 
IPTG  isopropyl-beta-D-thiogalactopyranoside 
K  lysine 
KBP 1.66 KIX-binding peptide 1.66 
KBP 2.20 KIX-binding peptide 2.20 
KBPo2 KIX-binding peptoid 2 
KD  equilibrium dissociation constant 
koff  dissociation rate constant 
KCl  potassium chloride 
L  leucine 
L  liter 
LB  Luria-Bertani media 
LBD  ligand binding domain 
M  methionine 
M  molar 
mg  milligram 
mL  milliliter 
mM  millimolar 
µg  microgram 
µL  microliter 
MDM2 mouse double-minute 2 
Med15P Med15 potentiator 
Med15DM Med15 double mutant 
Mtx  methotrexate 
MW  molecular weight 
 xi 
N  asparagine 
Na2CO3 sodium carbonate 
NaOH  sodium hydroxide 
NEAA  non-essential amino acids 
ng  nanogam 
nm  nanometer 
nM  nanomolar 
NMR  nuclear magnetic resonance 
NTP  nucleotide triphosphate 
OD600  optical density at 600 nm 
OD420  optical density at 420 nm 
ONPG  o-Nitrophenyl-beta-galactopyranoside 
Opti-MEM reduced-serum modified Eagle’s medium 
OxDex  oxidized dexamethasone 
P  proline 
P  total protein concentration in (mg/mL) 
P201  peptide 201 
p53  protein 53 kilodaltons 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PNA  peptide nucleic acid 
pLysE  plasmid encoding high levels of T7 lysozyme 
pLysS  plasmid encoding low levels of T7 lysozyme 
PSG  penicillin-streptomycin-glutamine 
Q  glutamine 
R  arginine 
REST/NRSF repressor element-1 silencing transcription factor/neuron restrictive  
  silencer factor 
RLU  relative light units 
RNA  ribonucleic acid 
RPM  rotations per minute 
S  serine 
s  second 
SAGA  Spt-Ada-Gcn5-Acetyltransferase complex 
SDOM  standard deviation of the mean 
SDS  sodium dodecyl sulfate 
SRB4  suppressor of RNA polymerase B 4 
SV40  simian virus 40 
T  threonine 
t  time 
TBP  TATA binding protein 
TIS  triisopropyl silane 
TFIIB  transcription factor IIB 
TFA  trifluoroacetic acid 
TFO  triplex forming oligonucleotide 
Tris  Tris(hydroxymethyl)aminomethane 
 xii 
U  uracil 
UAS  upstream activating sequence 
UV-Vis ultraviolet-visible 
V  valine 
VP-16  viral protein-16 
Vs  volume of lysate added 
VT  total volume 
W  tryptophan 
XLY  LTGLFVQDYLLPTCIP 
XLR  LTGLFVQDRLLPTCIP 








Chair: Anna K. Mapp 
 
 The strict regulation of transcription is essential for the survival of an organism.  
Nearly every human disease is associated with mis-regulated transcription as either a 
cause or an effect.  This realization has brought about significant research efforts to both 
better understand the mechanism of eukaryotic transcription and to create small 
molecules capable of modulating this complex process. 
 Transcriptional activator proteins play a critical role in the control of gene 
expression.  Minimally composed of a DNA binding domain and an activation domain, 
they are responsible for the levels and time-course of expression of a particular gene. The 
creation of activator artificial transcription factors (ATFs), non-natural replacements for 
activators, has provided mechanistic details about this process and have potential as 
therapeutics to reprogram aberrant patterns of gene expression.  Chapter I details our 
current understanding of activators and progress that has been made in the creation of 
activator ATFs. 
 xiv 
Features of activators that contribute to their potency (the levels of transcription elicited) 
are poorly understood.  Until recently, it was believed that the strength of an activator 
was directly correlated with its affinity for coactivator targets.  Chapter II details our 
studies of activator ATFs that target the coactivator Med15 in order to reveal other 
functional contributors to activator potency. Specifically, these studies demonstrated the 
importance of binding site location and secondary interactions that prevent non-
productive binding and proteolytic degradation to the potency of a transcriptional 
activator. 
 Endogenous activators bind to an overlapping set of coactivator targets yet exhibit 
very little sequence homology outside of a general amphipathic composition.  The 
permissive nature of coactivator binding sites led us to design a series of small molecules 
which presented functionality commonly observed in amphipathic activators to be used 
as an activation domain.  Chapters III and IV detail the cell-free and cell-based assays 
which demonstrate the utility of an isoxazolidine scaffold for this purpose.  Remarkably, 
they represent the first small molecule activation domain with activity in living cells. 
Early mechanistic work suggests that they function by a mechanism analogous to their 
natural protein counterparts. Future studies of these molecules include in-depth 
mechanistic investigations as well as structural optimizations to increase potency, 
experiments that are detailed in Chapter V.
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Chapter I 
Current Picture of Transcriptional Activators 
 
A.  Significance  
 Even though every cell in the human body contains the same genetic information, 
each tissue is able to specialize to carry out specific functions.  While the DNA code of a 
cell in the brain is the same as one in the heart for example, each is able to carry out its 
own unique task.  To understand the origin of this cell type differentiation, one must look 
not only at the genetic code, but also at how this code is read, or transcribed.  It is the 
differential expression of genes that accounts for cell type specificity and in turn, the vast 
specialization of each cell in the human body.   
 In 2001, the sequencing of the human genome was completed, putting forth the 
framework for an unprecedented understanding of the link between genetics and disease.1  
In fact, misregulation of gene expression is linked to almost every human disease, either 
as the cause for or effect of a particular disorder.2,3  The discovery of molecules to 
reprogram patterns of gene expression would result in the development of powerful tools 
for the treatment of countless human diseases.  While this long term goal certainly 
remains on the distant horizon, significant strides have been made towards its end.4  The 
project herein describes efforts towards the development of a small molecule 
transcriptional activation domain, a molecule capable of upregulating gene expression 
when localized to DNA. 
 2 
B.  Modularity of Transcriptional Activators 
 In eukaryotic cells, transcriptional regulator proteins are responsible for the levels 
and time-course of gene expression.5  Transcriptional regulators are capable of binding to 
a specific site on DNA and effecting gene transcription.  Repressors typically inhibit 
transcription by recruiting corepressor proteins and, conversely, activators up-regulate 
transcription through binding and recruiting a host of coactivators.  The proteins recruited 
by activators are responsible for modifying histones, allowing access to a particular gene, 
as well as forming the pre-initiation complex with RNA polymerase II, the first key step 
in gene transcription (Figure I-1).4   
 
Figure I-1: Activators bind to DNA and recruit chromatin modifying enzymes (CME) 
and the RNA polymerase holoenzyme to a specific gene in order to up-regulate 
transcription. 
 
 Activator proteins are composed of at least two distinct domains.  The DNA 
binding domain (DBD) is responsible for localizing the regulator to a specific site on 
DNA, imparting the majority of the gene targeting, and the activation domain (AD) 
determines the level of gene transcription through its contacts with other proteins.6  The 
two domains are connected through covalent or non-covalent interactions in order to 
regulate a specific gene.  There is often a linker region between the two domains that 
allows dimerization of the regulator, leading to increased potency.   The separable nature 
of these domains was first demonstrated by the Ptashne lab in a series of “domain 
CME’s 
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swapping” experiments conducted in Saccharomyces cerevisiae.7  In order to determine if 
the two domains could function independently, a hybrid protein was constructed with the 
DBD of the bacterial repressor LexA and the AD of the yeast activator protein Gal4, a 
potent activator responsible for regulating the galactose metabolism genes in yeast.   The 
hybrid protein was able to activate a reporter gene bearing binding sites for the bacterial 
repressor to the levels of the activator Gal4.  Furthermore, activation was no longer 
observed in genes bearing the Gal4 binding site.  The separable nature of these two 
domains suggested a straightforward mechanism for the construction of activator 
artificial transcription factors (ATFs) incorporating the binding specificity of one protein 
with the activity of another (Figure I-2). 
 
 
Figure I-2: The DNA binding domain (DBD) of an activator (blue) determines the gene 
to be modulated while the activation domain (AD) (red) determines potency.  This allows 
for the creation activator ATFs with unique specificity and potency. 
 
 
C.  Transcription and Disease 
 As previously stated, aberrant patterns of gene expression can often lead to 
disease.  One disorder in which this link has been thoroughly investigated is 
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medulloblastoma, one of the most malignant pediatric brain tumors.8  It is believed that 
this condition arises from undifferentiated cells in the cerebellum.   These cells are often 
observed to overexpress repressor element-1 silencing transcription factor/neuron-
restrictive silencer factor (REST/NRSF), a global transcriptional repressor responsible for 
inhibiting transcription of most of the neuronal differentiation genes by binding to a 23bp 
consensus sequence.  This protein, which is expressed at high levels in nearly all non-
neuronal cells in the body, inhibits transcription through the recruitment of corepressor 
proteins such as CoREST, Sin3A, and histone deacetylaces (Figure I-3a).8  In order to 
compete with this overactive repressor, Majumder and coworkers decided to infect 
medulloblastoma cells with an adenovirus harboring a chimeric activator ATF composed 
of the DBD of REST/NRSF and the AD of VP16, a potent viral coactivator protein.9  It 
was thought that by taking advantage of the modular nature of transcriptional regulators 
and activating the genes that are being inhibited by overexpressed REST/NRSF, the 
neuronal cells could then differentiate and prevent tumorgenesis.  While this was not the 
exact result that was observed, the REST-VP16 conjugate did lead to apoptosis in tumor 
cells both in vitro and in vivo (Figure I-3).  It was speculated that the genetic instability 








a)       b) 
    
Figure I-3: (a) Over-expression of REST, a transcriptional repressor, is often observed in 
medulloblastoma. REST expression inhibits neuronal differentiation genes through the 
recruitment of a host of co-repressor proteins.  (b) Treatment with REST-VP16 activates 
these inhibited genes leading to cell apoptosis and decreased tumor growth.  Figure from 
(9). 
 
The ability of this exogenous activator ATF to counteract an endogenous repressor is a 
remarkable discovery and truly shows the potential of transcription-targeted therapeutics.   
Further, the development of a small molecule which could be used in place of the 
chimeric protein is likely to have enormous advantages in terms of delivery and cellular 
stability. 
  
D.  Transcriptional Activators 
 The discovery of the modular nature of transcriptional activators initiated an 
intense effort to structurally and functionally characterize the DBD as well as the AD of 
natural activators in order to eventually create artificial replacements.  Initial efforts 
towards characterizing the DBDs were quite successful leading to the discovery of 
numerous structural motifs, for example the helix-turn-helix motif observed in LexA and 
the Zn(II)2Cys binuclear cluster of Gal4.10-12  Structural characterization of the ADs 
proved to be much more challenging.   Activating regions generally remain unstructured 
in solution and become structured only upon binding their protein targets.  Additionally, 






Therefore, instead of structural categories, activators are typically characterized by the 
preponderance of certain amino acid residues such as proline-rich, glutamine-rich, or 
acid-rich.5,18-20  The most well studied activators, including the yeast activator Gal4, 
typically fall into the class of amphipathic or acid-rich activators.  These activation 
domains are found to contain a number of acidic and polar residues interspersed with 
hydrophobic amino acids (Figure I-4).  It is thought that while the polar residues are 
important for interacting with the solvent, many of the most important protein contacts 
involve the hydrophobic groups.  For example, mutations in any of three hydrophobic 
residues in the GCN4 central acidic activation domain (CAAD) (M107, L123, and F124) 
to alanine greatly diminish its ability to activate transcription in vivo and its ability to 
bind to coactivator targets in vitro.21,22 
a)     b) 
VP16      
441  DFDLDMLG 448 
p53      
9   SVAPPLSQETFSDLW 23 
 
 
Figure I-4: a) Acidic activation domains are composed of interspersed polar (red) and 
hydrophobic (green) residues. b) Althoguh unstructured in solution, the p53 activation 
domain forms a helix upon binding to one of its protein targets (Mdm2). Figure Reprinted 
form (16) with permission. 
 
 Further obscuring mechanistic details of transcriptional activators is their 
promiscuous binding profiles that are often observed.   While the DBD of an activator 
acts through targeting a specific binding site, the activation domain is capable of binding 
to numerous protein targets.23  For instance, the Gal4 activation domain has been shown 
to interact in vitro with the transcriptional machinery proteins TBP, Med15, Cdk8, Srb4, 
SWI/SNF, and others as well as the chromatin modifying complex SAGA.24  Attempts at 
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determining the functionally relevant targets are quite challenging due to the redundancy 
of the various binding surfaces. Disruption of one interaction can often be compensated 
with a non-physiologically relevant one.  While the abundance of protein targets within 
and outside the transcriptional machinery makes constructing a detailed picture of 
activator function challenging, it is likely a necessary feature of these regulators.  The 
initiation of transcription involves interactions between dozens of different proteins all of 
which must localize to a specific gene in a particular way. 
 
E.  Regulation of Activator Interactions 
 In addition to targeting coactivators, ADs also bind to proteins which control the 
time-course of gene activation.  For example, Gal4 has also been shown to bind to Sug1 
and Sug2, two components of the proteosome.25,26  This interaction likely leads to 
degradation of the activator and a decrease in activated transcription.  If the cell is to 
maintain strict control of gene expression, it must allow activation only when the gene 
product is needed and degradation of the activator serves as a useful mechanism.  
 Another method to prevent uncontrolled activation is through the binding of 
masking proteins.  Masking proteins bind to an activator, preventing it from making key 
contact and/or trafficking to the nucleus.  The usefulness of masking proteins as 
regulatory elements can be observed with the Gal4-Gal80 interaction.  In the absence of 
galactose, when the galactose metabolism gene products are not needed, the Gal4 
activation domain is tightly bound to Gal80 and incapable of activating transcription.  
However, the presence of galactose causes the Gal3 protein to interact with Gal80, 
leading to a conformational change and thereby allowing Gal4 to activate transcription.  
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This system serves to both prevent unnecessary transcription and to protect Gal4 from 
degradation.27  Although inter-molecular masking is most common, there are also several 
examples of intra-molecular masking.  For example, the Leu3 activator protein, 
responsible for the induction of leucine biosynthesis genes, contains an intra-molecular 
binding site for its activation domain.28  This allows the protein to induce gene expression 
only in the presence of a necessary precursor.  This intra-molecular masking has also 
since proven to be an extraordinary design feature for the creation of novel artificial 
transcriptional activators.29 
 
F.  Activation Domain Replacement 
 Transcription-based therapeutics capable of regulating specific genes to 
predetermined levels have the potential to treat a host of ailments.  Towards this end, 
artificial replacements for both the DBD as well as the AD of transcriptional activators 
have been and continue to be investigated.  Much of the early work towards the 
development of artificial replacements for transcriptional activators focused on the 
replacement of the DBD.6  Since it is the DBD that imparts the majority of the specificity 
of transcriptional activators, discovering replacements capable of targeting specific DNA 
sequences is extremely important.  Early work toward elucidating the structure and 
function of natural DBD was quite successful, leading to a detailed picture of DNA 
binding from a number of natural transcriptional activators as well as repressors (Figure 
I-5).10  In order to reprogram aberrant patterns of gene expression, one could use a unique 




Figure I-5: The structure of the GCN4 DBD bound to its requisite DNA target.  Figure 
reprinted from (30) with permission from Elsevier.  
 
 Genetic selection was initially used in order to create zinc finger protein DBDs 
capable of targeting unique sites within the genome.31  Phage display was carried out in 
order to elucidate zinc fingers capable of binding to unique tri-nucleotide sequences.  
These zinc fingers could then be combined to target more specific sites.  In theory, six 
zinc fingers would be capable of targeting an 18bp sequence, which would be specific 
within 68 billion base pairs, or 20 human genomes.  While this method was found to be 
successful, the creation of non-peptidic DBDs carries more potential to be used as 
therapeutics.  Because peptidic DBDs are poteolyzed in the cell, synthetic DBDs would 
have much longer lifetimes in vivo and therefore could much more readily be converted 
into drugs.   
 Efforts towards creating non-peptidic DBD were also quite successful.  Triplex-
forming oligonucleotides (TFOs) capable of recognizing unique DNA sequences through 
formation of Hoogsteen base pairs with double stranded DNA and peptide nucleic acids 
(PNAs) in which the phosphodiester bonds in the backbone have been replaced with 
amides were the first successful replacements discovered (Figure I-6).32,33  Both of these 
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artificial replacements are able to bind to DNA in a highly specific manner.  In fact, there 
are numerous examples of activator ATFs in which these classes of DBDs are used.   
 a)        b) 
    
Figure I-6: (a) Triplex forming oligonucleotides take advantage of Hoogsteen base pairs 
in order to specifically interact with double stranded DNA.  (b) Peptide nucleic acids 
contain an amide backbone in place of the sugar of DNA.  This increases stability while 
allowing specific interactions with DNA and RNA. Figures from (31, 32). 
 
Perhaps the most notable replacement for the DBD was discovered by the Dervan group 
and was modeled after the natural product distamycin.  These polyamide small molecules 
are capable of recognizing and binding each of the four possible DNA base pair 
combinations (Figure I-7).34  They bind to the minor groove of DNA in a manner that 
does not severely affect DNA’s overall structure and have also been shown to activate 




Figure I-7: (a) Pyrrole-imidazole polyamides are capable of binding to each of the four 
DNA base pair combination through the asymmetric hydrogen bond donors and acceptors 
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presented.  (b) The polyamide binds as a dimer in the minor groove of DNA causing little 
distortion on the overall structure of DNA. Figure from (33). 
 
 The construction of artificial replacements for the DBD has been made possible 
by the vast structural data available on their natural counterparts.  This has not, however, 
been the case for developing artificial replacements for the AD.  As previously 
mentioned, AD’s typically remain unstructured in solution and show significant 
secondary structure only when bound to a protein target.  This has made it very 
challenging to determine the necessary structural motifs for activator binding and to 
incorporate them into small molecule replacements.  Furthermore, the AD is responsible 
for far more than a simple binding interaction.  It is the AD that controls the time course 
and levels of gene expression, so it must be able to respond to extra-cellular signals, 
undergo covalent modifications, traffic to the nucleus, and activate a gene to a 
predetermined level.6  Integrating even some of these properties into small molecule 
replacements is certainly a formidable challenge and, in fact, at the onset of this research, 
there was not a single report of a small molecule capable of activating gene transcription. 
 
G.  Small Peptidic Activation Domains 
 Initial efforts towards creating artificial activation domains relied on the use of 
known activating regions from endogenous proteins.  While the specific structures of 
activating regions has been very challenging to determine, the regions responsible for 
activating transcription in a particular activator protein could be determined from deletion 
experiments.36  This allowed for the construction of the first artificial activators 
composed of protein DBD’s coupled to peptidic AD’s.6  With further study, the peptidic 
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activation modules could be refined to very small sequences, such as the eight residues of 
the AD VP1 or the 14 residue AD ATF14, both derived from the potent viral co-activator 
VP16 (Figure I-8).37  Acidic ADs are often composed of surreptitious repeats of eight to 
ten amino acids and the minimal repeat itself can function as an AD when fused to a 
DBD.  A relatively small number of contacts are therefore necessary for an AD to interact 
with its coactivator target.  This can also be observed with the interaction between Mdm2 
and p53 (Figure I-4) where three key contacts are needed for the binding interaction.16 
 The p53●Mdm2 interaction also demonstrates another property of acidic 
activation domains: their propensity to form helices upon binding to their protein targets.  
This information in concert with the promiscuous nature of activator binding led the 
Ptashne lab to design a peptide predicted to form an amphipathic helix and to test its 
activity in vivo.35,38  As many different activation domains are able to target an 
overlapping set of sites within the transcriptional machinery, it was thought that a peptide 
capable of loosely mimicking a motif observed in acidic activators would also be able to 
activate transcription.  Remarkably, this 15 amino acid peptide named AH, for 
amphipathic helix, was able to activate transcription robustly in yeast.38  This was the 
first example of a rationally designed AD and gave tremendous insight into the nature of 
natural activators; that presenting an amphipathic face was sufficient to form interactions 
with coactivator targets.  If a small peptide designed to form a specific structural motif 
could activate transcription, then reproducing this affect with a small molecule could be 
envisioned (Figure I-8). 
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Figure I-8:  (a) Amino acid sequence of two minimal activation modules (VP1 and 
ATF14) and a sequence designed to form an amphipathic helix (AH) with charged 
residues in red, polar in green, and hydrophobic in blue.  All three of these sequences 
activate transcription when coupled to a DBD.  (b) Model of AH, demonstrating its 
amphipathic character.  
 
 A significant amount of information about activation domains demonstrates their 
promiscuous binding nature, but it was a set of “activator bypass” experiments that 
showed targeting a single protein in the transcriptional machinery could suffice to 
activate transcription.39,40  In these experiments, Med15 was expressed as a fusion protein 
with an endogenous DBD.  Med15 is a component of the mediator, a complex which 
interacts directly with RNA Polymerase II and has since been shown to be a target of 
both natural and artificial AD’s.41  This hybrid protein was able to act as an activator 
ATF, demonstrating that localizing a single component of the transcriptional machinery 
to a gene was sufficient to activate transcription.  This result was both an exciting 
discovery about activator function and also led the way to the development of numerous 
novel AD’s which could uncover more important properties of activator proteins.   
 With this in mind, peptide selections have been used to create novel activation 
domains.  In a peptide selection, the protein of interest is first immobilized on solid 
support and libraries of phage or bacteria expressing peptides on their coat proteins are 




AH:       ELQELQELQALLQQQ 
a) b) 
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then added to the immobilized protein.42,43  If the organism is capable of binding to the 
protein of interest, it is trapped on solid phase and can be amplified.  Through multiple 
rounds of panning, followed by DNA sequencing, peptides capable of binding to the 
protein with high affinity can be discovered.  This approach was taken by Montminy and 
coworkers to discover peptides capable of binding to the KIX domain of CBP, a 
component of the eukaryotic transcriptional machinery.44  The KIX domain has been 
shown to be a target of numerous transcriptional activators including jun, tax, c-Myb, 
HIV-tat, and others.45,46  If  small peptides were capable of making similar interactions 
with KIX, then they should suffice as an AD.  As expected, potent activation was 
observed in mammalian cells when KIX binding peptides were localized to DNA.  Upon 
further analysis, these peptide ligands could present amphipathic nature when modeled to 
a helical wheel (Figure I-9).44  This result further demonstrated the ability to replace 
protein ADs with small amphipathic molecules. 
 
    
Figure I-9: (a) Sequences of KBP 1.66 and KBP 2.20, the peptides discovered through 
phage display against the KIX domain, as well as the sequence of c-Myb, an endogenous 
activator which targets the KIX domain.  Acidic residues are in red and large 
hydrophobic residues in blue.  (b) Helical wheel diagram demonstrating the hydrophobic 
face (starred residues) which interacts with the KIX domain. 
KBP 1.66 SSLVDLIL 
 
KBP 2.20 WAVYELLF 
 




















 Phage display also proved to be a useful technique for understanding the link 
between interactions with masking proteins and interactions important for transcriptional 
activation.  As previously mentioned, in order to prevent nonspecific interactions and 
premature degradation and allow strict regulation of transcription, masking proteins 
which bind to activation regions are often employed.  While it had been shown that ADs 
were capable of interacting with numerous components of the transcriptional machinery, 
chromatin modifying enzymes, and masking proteins, it was not known whether the same 
chemical interactions were used in all cases.  To probe this question, the Kodadek lab 
used phage display to discover peptides which could interact with the Gal80 repressor.47  
If these peptides bound to a similar surface of Gal80 as the Gal4AD, one would expect 
them also to activate transcription.  Alternatively, if Gal80 blocks Gal4 transcription by 
binding to a surface other than the AD, the ligands would be unlikely to activate.  
Kodadek found that these peptide ligands were capable of upregulating transcription and 
could prevent Gal4AD from binding to Gal80, demonstrating that the same surfaces of 
Gal4 interact with both coactivators and masking proteins.  Further evidence to support 
this hypothesis was also revealed when it was shown that the Gal80 binding peptide 
interacted with the coactivator Med15, one of the targets of Gal4.    
 
H.  Non-Peptidic Transcriptional Activators: 
 Although peptidic activators have certainly provided a plethora of information 
about factors affecting potency, important binding interactions, and structural motifs of 
ADs, the next step towards transcription based therapeutics lies in the advancement of 
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non-peptidic replacements for the AD module.  The first example of a non-peptidic 
transcriptional activator was reported by the Ptashne lab in 2003.48  As mentioned, 
transcriptional activators must interact with DNA and components of the transcriptional 
machinery.  As numerous aptamers, DNA or RNA oligomers capable of binding to 
protein surfaces, have been described, the Ptashne lab thought it might be possible to take 
advantage of the binding properties of RNA and create an RNA AD.  Indeed, a series of 
hairpin oligonucleotides were capable of upregulating transcription in yeast when 
localized to DNA.  This remarkable finding further confirmed the permissive nature of 
activator binding sites and demonstrated the utility of creating non-peptidic AD’s. 
 Since this discovery, two other small molecule ADs and one peptoid AD have 
been described.  The first came from the Mapp research lab and is discussed in Chapter 
III.  This involves the use of an isoxazolidine scaffold bearing functionality often 
observed in endogenous AD’s.49,50  This scaffold was chosen due to its ease of synthesis 
and its ability to project functionality in a three dimensional array, similar to the helices 
of natural AD’s formed upon binding to their protein targets (Figure I-10).51  Through the 
small molecule’s interactions with the shallow, permissive binding surfaces of 
coactivators, it is able to activate transcription when localized to DNA.  This activation is 
observed both in vitro as well as in cell culture. 
  a)          b) 
 
Figure I-10:  The rigid isoxazolidine scaffold is capable of displaying varied 
functionality which generally mimics common residues of endogenous activators. 
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 Shortly after we reported this small molecule AD, the Uesugi lab described 
another molecule capable of modulating transcription.  This molecule, named 
wrenchnolol, was initially discovered through a combination of rational design and 
screening for compounds capable of disrupting the interaction between the ESX 
activation domain and one of its coactivator targets Sur2 (Figure I-11a).  Through binding 
of Sur2, wrenchnolol was capable of disrupting activated transcription by ESX and to a 
lesser extent, other activation domains.  When wrenchnolol was localized to DNA 
through a polyamide DBD it was able to activate transcription, likely through these same 
binding interactions, yet its lack of cell permeability prevented its activity in cells. 
 The third example of a non-biopolymer activation domain was reported by the 
Kodadek lab in 2005.  A peptoid screen was employed to discover molecules that could 
interact with the KIX domain of the coactivator CBP, a target of numerous natural 
activators (Figure I-11b).  Peptoids, N-substituted glycine oligomers, are resistant to 
proteolysis and have proven useful as protein binding agents due to their unique 
secondary structure and the diverse functionality that can be incorporated within them.  
The peptoid screen identified two molecules capable of binding to the KIX domain, 
although one of them was extremely hydrophobic and appeared to interact solely through 
nonspecific hydrophobic interaction.  The second peptoid, KBPo2, robustly activated 







Figure I-11: a) Wrenchnolol and b) KBPo2 activate transcription when localized to 
DNA. 
 
A more recent report by the Kodadek lab reveals a smaller peptoid screened against the 
same protein which upregulates transcription when coupled to a polyamide DBD, 
representing a fully non-biopolymer activator ATF.53 
 From the first reports of the unique, separable domains of transcriptional 
activators to the more recent replacements of both with small molecules, our view of 
transcriptional activators has changed dramatically over the last 20 years.  We now have 
the ability to create artificial transcriptional activators composed of numerous different 
non-natural domains capable of controlling transcription of many different genes with 
varying potencies (Figure I-12).   
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Figure I-12: Transcriptional activators are composed of a DBD and AD.  Numerous 
artificial counterparts have been described for each domain resulting in the creation of 
activator ATFs. 
 
 In order to further expand available ADs, my research has focused on the 
development of a small molecule-based AD.  Creating this activator required that a 
number of questions about the origin of activator potency be addressed.  Initially we used 
small peptides to elucidate the effects of binding affinity and secondary interaction on 
activator potency (Chapter II).  With this information in hand our lab designed and 
synthesized a small molecule we believed could modulate transcription (Chapter III).  
Indeed, this resulted in the first small molecule AD.  After determining the activity of 
these small molecules in vitro, my work has centered on understanding how this small 
molecule could reconstitute the activity of a protein AD and furthermore if activation 













approach has not only expanded the repertoire of available AD’s but has also paved the 
way for other scaffolds designed to regulate transcription. 
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Features Affecting Activator Potency1 
 
A.  Background 
 Transcriptional activators play a critical role in the regulation of gene expression.  
The growing link between misregulation of transcription and disease has led to an effort 
to create activator artificial transcriptional factors (ATFs) capable of repairing aberrant 
expression patterns.1-3  Minimally composed of a DBD and an AD, transcriptional 
activators are responsible for regulating the time course and the levels of transcription of 
specific genes.4  The DBD imparts the majority of the specificity through localizing the 
transcriptional activator to a specific site in the genome and the AD controls the potency 
of the activator through contacts with chromatin modifying enzymes and components of 
the RNA polymerase holoenzyme.4  However, the factors that contribute to activator 
potency – the extent to which an activator up-regulates transcription - remain poorly 
understood.  At the onset of this work, the prevailing model was that the affinity of an 
activator for the transcriptional machinery directly correlated to the extent to which that 
                                                
1 Portions of this chapter were taken from Wu, Z.; Belanger, G.; Brennan, B. B.; Lum, J. K.; Minter, A. R.; 
Rowe, S. P.; Plachetka, A.; Majmudar, C. Y.; Mapp, A. K. Journal of American Chemical Society 2003, 
125, 12390-12391. and Lu, Z.; Rowe, S. P.; Brennan, B. B.; Davis, S. E.; Metzler, R. E.; Nau, J. J.; 
Majmudar, C. Y.; Mapp, A. K.; Ansari, A. Z. Journal of Biological Chemistry 2005, 280, 29689-29698.  
The peptide screen (Figure II-2) was carried out by Aaron Minter and Annette Plachetke.  I carried out the 
β-galactosidase assays on the Med15 ligands (Figure II-3) and along with Dr. Zhiqian Wu, determined the 
binding affinities (Figure II-4).  Figures II-6, II-7, II-10, II-11, and II-12, represent work carried out by our 
collaborator (Dr. Aseem Ansari) at the University of Wisconsin Madison.  The work represented in Figures 
II-8, II-9, and II-13, I carried out in collaboration with Steven Rowe. 
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activator up-regulated transcription. The implication for the development of small 
molecule transcriptional activators was that they needed to interact with coactivator 
binding surfaces with high affinity (nanomolar or subnanomolar dissociation constants); 
this represented a potentially significant impediment to small molecule activation 
domains since the identification small molecules with this level of affinity for protein 
surfaces has been a longstanding challenge. 
One aspect of the previous studies of activator-coactivator interactions that was 
problematic was that they were often carried out with transcriptional machinery proteins 
shown not to be physiologically relevant activator targets. TBP, for example, was often 
examined in these studies. In this Chapter, we describe the use of artificial transcriptional 
activators that specifically interact with the coactivator Med15 to demonstrate that 
affinity and potency are not always correlated. Further, these studies revealed that 
micromolar dissociation constants are sufficient for good activity. In addition, we found 
that secondary binding interactions, so-called ‘masking’ interactions, can also contribute 
significantly to the ability of an activator to up-regulate transcription 
 
B.  Beyond Binding Affinity 
 Although the promiscuous nature of AD binding has made it challenging to 
unambiguously identify which protein targets are most important for the initiation of 
transcription, the Mediator complex has emerged as a common target of numerous 
endogenous activators.5-7  The Mediator is a multi-protein complex (20-25 proteins in 
yeast) believed to act as a bridge between DNA bound transcriptional activators and 
RNA polymerase II (Figure II-1).  This complex is composed of a head and middle 
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region largely responsible for interacting with RNA polymerase II and a tail region which 
is proposed to be targeted by endogenous activators.8   
 
Figure II-1:  a) Mediator, shown in this electron micrograph, is composed of a head (H) 
and middle (M) regions which contact RNA Polymerase II directly as well as a tail (T) 
region which is targeted by transcriptional activators. This figure was taken from (8) b) 
The yeast Mediator is composed of 20 proteins.  Med15 (highlighted in blue) is located in 
the tail region and has been shown to interact with numerous different transcriptional 
activators. 
 
Within the tail region of the yeast Mediator complex lies Med15, a protein that has been 
shown to interact with a number of artificial and natural ADs.8,9  The most compelling 
evidence of interactions between Med15 and endogenous activators was recently 
presented by Hahn in a series of photo-cross-linking experiments.  The incorporation of a 
cross-linking agent into the AD of Gal4 identified a Med15 interaction in the context of 
transcriptional initiation.10  Further evidence of Med15 as an activator target came from a 
series of activator bypass experiments in which Med15 was shown to activate 
transcription when directly fused to a DBD.11,12  The substantial amount of evidence for 
Med15 acting as a cellular target of activators prompted us to screen a peptide library 
against this protein in search of novel ADs. We inferred that these peptidic ligands would 
function as ADs through their interactions with Med15. A comparison of the affinity of 
these activation domains for Med15 versus their ability to up-regulate transcription would 
-Nut1, Srb4, Med1, 
Srb6, Srb5, Med6 
Med7, Med4, Rox3 
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then test the activity-affinity connection. The large diversity of a peptide library was also 
likely to produce peptide sequences not commonly observed in known activating regions 
with unique binding sites on the protein.  In this case, we could also determine the 
importance of binding site location on activator potency.13 
 We designed two libraries, each with four variable positions.  Our first library 
(AXXXXLSE) was designed to bias for peptides which would bind similar sites as 
endogenous activators, as the LSE sequence is common among helix forming 
amphipathic ADs.  Our second library (AXXXXPSE) contained a proline which would 
prevent helix formation and would probably produce ligands which would bind surfaces 
of Med15 which are not targeted by endogenous activators.  An ELISA screen was then 
carried out by another graduate student (Aaron Minter) with GST-Med15 (186-619) 
against the two peptide libraries.  This region of Med15 was chosen for the screen since it 
is the largest portion of Med15 that can easily be expressed.  In addition, this region has 
been shown to interact with endogenous and artificial ADs.  The screen produced a total 
of 37 peptide ligands (Figure II-2).  Ligands were found to be either amphipathic in 
sequence, hydrophobic, or contained an excess of positive charge. 
 
Figure II-2:  Libraries used in the Med15 screen.  The peptide screen produced 37 
ligands which interact with Med15.  The peptides capable of upregulating transcription 





 Two members of my research lab (Garrette Belanger and Jenifer Lum) coupled 
each ligand to a protein DBD and tested its ability to activate transcription with a β-




Figure II-3: Med15 Ligands #17 and #28 activate transcription when fused to the DBD 
of the bacterial protein LexA in a yeast strain bearing LexA binding sites upstream of a 




Interestingly, despite their ability to activate transcription, neither activator resembles 
known activating regions.  Peptide #17 bears a significant amount of positive charge and 
peptide #28 is extremely hydrophobic, two features not commonly observed with 
endogenous ADs.  It was therefore likely that these peptides were targeting unique sites 
on Med15 which do not typically interact with endogenous ADs.   
 Along with Dr. Zhiqian Wu, a postdoctoral fellow in my research lab, I carried 
out fluorescence polarization binding experiments with the active peptidic ligands along 
with the controls VP2 and P201.  We found that all of the ligands bound to Med15 with 
low micromolar dissociation constants; the most potent (XLY) and the least potent (#17) 




























 In order to determine if the peptides were targeting different surfaces on Med15, a 
set of competition binding experiments were performed by Dr. Zhiqian Wu.  In these 
experiments, each peptide was fluorescently labeled and incubated with Med15 at a 
concentration that allowed saturated binding.  Following this pre-incubation, an excess of 
unlabeled peptide was titrated in.  As expected, unlabeled peptide of the same identity 
competed for binding and resulted in a decrease in fluorescence polarization.  However, 
when any of the other peptides was titrated, no competition was observed, demonstrating 
the unique nature of the binding sites. 
    




Figure II-4:  (a) Dissociation constants for each of the ADs and their ability to 
upregulate transcription.  (b) Each activation domain binds to unique sites on Med15. 
 
Since each of the four activators bind to different sites on Med15, it is unlikely that 
binding affinity alone leads to the varied function observed.  One striking result from this 
study was the potency of P201 when compared to the other peptidic ADs. Determining 
the factors that lead to this extraordinary activity could uncover design principles that 








2.2 ± 0.2 µM 
7.3 ± 2.4 µM  
4.3 ± 1.4 µM 












C.  An Unusually Potent Peptidic Activation Domain 
 P201 was discovered by the Ptashne lab through a screen of random peptides that 
when fused to the first 100 residues of Gal4, comprising the DBD and dimerization 
domain (dd), were capable of upregulating transcription in a gene bearing the Gal4 
upstream activating sequence (UAS).  Remarkably, this small hydrophobic peptide with 
the sequence YLLPTCIP, lacking any acidic residues often observed in ADs, is capable 
of activating transcription as well as the full Gal4 activator protein (1-881) when fused to 
Gal4 (1-100).9,14  Further studies also revealed that P201 was entirely dependent on the 
mediator component Med15.  In fact, a single point mutation in Med15 (T322K) 
completely abrogates the ability of Gal4 (1-100)-P201 to activate transcription in vivo 
and the ability of P201 to bind to Med15 in vitro.9,15  This is quite an unusual result since 
activators typically target numerous proteins in the transcriptional machinery and this can 
somewhat compensate for the loss of any single interaction.   
 Despite its unusual properties, P201 remains one of the two potent artificial 
activators with robust activity in vivo.  The other is Gal4 (1-100) by itself in a yeast strain 
bearing a single point mutation in Med15 (N342V).16,17  This mutant form of Med15 has 
been named Med15P for its ability to potentiate activation by Gal4 (1-100), a protein 
which does not act as a transcriptional activator in wild-type yeast.  Through extensive 
NMR studies, the Ptashne lab determined the interaction between Med15P and the Gal4 
dimerization domain (Gal4dd) involved the largely hydrophobic amino acid residues of 
loop 1 and helix 3 binding to the hydrophobic surface created by the N342V mutation 




Figure II-5:  (left) NMR structure of the Galdd with helix 3 and Loop 1 indicated.  (right) 
Residues found to be important for interacting with Med15P are colored in red. Figure 
from (14). 
 
 We initially hypothesized that the potent activity of Gal4 (1-100)-P201 might be 
the result of a combination of P201’s affinity for Med15 as well as residual affinity of 
Gal4dd to wild type Med15.  In order to address this possibility, a series of β-
galactosidase assays were carried out in the lab of one of our collaborators, Dr. Aseem 
Ansari at the University of Wisconson, Madison.  In these experiments, the Ansari lab 
examined the ability of Gal4 (1-100)-P201 and Gal4 (1-100) to activate transcription in 
yeast strains bearing wild type or mutant forms of Med15.  The first mutant strain 
contained Med15 with the T322K mutation, the mutation which prevents P201 from 
interacting with Med15.  The second mutant yeast strain contained the N342V mutation, 
the Med15P mutant which promotes an interaction with Gal4dd.  Thirdly, a yeast strain 
bearing Med15 double mutant (Med15DM) containing both T322K and N342V was 
tested. 
 As expected, our collaborators observed that Gal4 (1-100)-P201 activated 





bearing the T322K mutation (Figure II-6 A, B).  Furthermore, Gal4 (1-100) was inactive 
in both of these strains, as they do not contain the mutation which promotes an interaction 
(Figure II-6 C, D).  In addition, Gal4(1-100) was active in both the Med15P strain as well 
as the Med15DM strain, demonstrating that the second mutation does not prevent an 
interaction between Gal4dd and Med15P (Figure II-6 E, F).  Although the Med15P strain 
contains binding sites for both Gal4 (1-100) as well as P201, activation elicited by Gal4 
(1-100)-P201 was comparable to levels observed with the wild-type Med15 strain (Figure 
II-6 G).  In the final experiment, the ability of Gal4 (1-100)-P201 to activate transcription 
in a yeast strain with Med15DM was assessed.  Since Gal4 (1-100) is capable of 
activating transcription in this strain, it would be expected that despite the disruption of 
the P201-Med15 interaction, Gal4dd could interact and upregulate transcription.  
However, activation was severely diminished in this strain (Figure II-6 H).  This suggests 
that P201 is able to block the interaction made by the Gal4dd.  Subsequent experiments 
were then designed to elucidate the nature of this interaction. 
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Figure II-6:  A series of β-galactosidase assays carried out by our collaborators.  
Interactions are represented by arrows, and disrupted interactions are represented by 
crossed out arrows.   
  
 While the in vivo experiments described indicate the Gal4dd is incapable of 
making an interaction with wild type Med15, earlier mutagenesis experiments carried out 
by the Ptashne lab have shown that at least part of the Gal4dd is required for P201 
function.  In order to examine the role of helix 3 of the Gal4dd in P201-mediated 
activation, the Ansari lab performed a series of alanine scanning mutagenesis 
experiments.  In order to prevent any potential impact of the scan on DNA binding, the 
DBD of Gal4 was replaced by the bacterial DBD LexA.  This experiment indicated Gal4 
(93-100) was essential for P201 function and therefore all in vitro binding experiments 
were performed with the minimal P201 peptide Gal4(93-100)-P201, 
LTGLFVQDYLLPTCIP), referred to as XLY (Figure II-7). 
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Figure II-7: Residues 93-100 of Gal4 are necessary for P201 function. 
 
D.  Binding Experiments 
 The activation data suggests an interaction between XLY and the Gal4dd.  In order 
to more fully investigate this interaction, Steven Rowe and I carried out a series of 
fluorescence polarization experiments.  For this purpose, XLY was synthesized by 
standard methods and fluorescently labeled.18  In addition, Gal4dd and the central portion 
of Med15 (residues 186-619) were expressed as GST fusion proteins and purified. 
 As demonstrated in figure II-8, XLY interacts with both Med15 and Gal4dd with 
micromolar binding affinity, with KDs of 2.2 µM and 5 µM respectively (Figure II-8).  
Additionally, XLY binds to Gal4dd in the context of Gal4dd-P201, albeit with a 3-4 fold 
reduction in binding affinity, indicating that the fused P201 does not prevent the 
XLY●Gal4dd interaction (Figure II-8).  As a control, we also looked at the interaction of a 
mutant version of P201 which does not activate transcription in vivo.  This peptide, 
referred to as XLR, contains a tyrosine to arginine mutation, resulting in the sequence 
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LTGLFVQDRLLPTCIP.  Binding assays with this version of P201 did not show 
appreciable binding to Med15, Gal4dd, or Gal4dd-P201. 
 Steve and I next tested to see if XLY would interact with Med15 bearing either the 
N342V mutation (Med15P) singly or in combination with the T322K mutation 
(Med15DM).  Consistent with the in vivo data, this mutation caused a 3-fold reduction in 
affinity for Med15P (Figure II-8).  Also consistent with the in vivo results, XLY did not 
bind to Med15DM within the limits of our assay. 
 
Figure II-8: Binding affinities of XLY for Med15, Gal4dd, Gal4dd-P201, and Med15P. 
 
XLY + Med15P XLY + Gal4dd- P201 
[GST-Med15(186-619)] (µM) 





 NMR studies of the Gal4dd indicate the presence of several solvent exposed 
hydrophobic residues.17  XLY is also a very hydrophobic peptide leading to the possibility 
that the interaction observed is simply a nonspecific hydrophobic interaction.  In order to 
probe the specificity of the interaction between XLY and Gal4dd, we decided to examine 
interactions between Gal4dd and the hydrophobic peptide discovered in the peptide screen 
previously discussed (AHYYYPSE).  This peptide binds to Med15 with comparable 
affinity to XLY, yet does not activate transcription as robustly.  If the origin of P201’s 
activity lies in its ability to interact with Gal4dd, then we would not expect the weaker 
activation domain AHYYYPSE to also interact.  This was in fact the case, as illustrated   
in Figure II-9.  Consistent with this result, it also does not inhibit activation by Gal4dd in 
yeast strains bearing Med15DM.  In further experiments, we observed that XLY does not 
bind to bovine gamma globulin, a protein often observed to interact with hydrophobic 
surfaces (figure II-9).  This data, taken together, demonstrates that the Gal4dd●XLY 
binding event is not simply the result of nonspecific hydrophobic interactions. 
 
Figure II-9: The hydrophobic Med15 ligand does not interact with the Gal4DD.  In 
addition, XLY does not bind nonspecifically to the hydrophobic protein bovine γ-
globulin.   
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 Another binding event of interest in this system is the interaction between Gal4dd 
and the various mutants of Med15.  Due to the large size of these proteins, fluorescence 
polarization experiments could not be performed to determine the binding affinity.  The 
affinities were thus determined by our collaborators at the University of Wisconsin, 
Madison, through the use of electrophoretic mobility shift assays (Figure II-10).   In this 
series of experiments, DNA bound Gal4 (1-100) (containing the Gal4 DBD as well as the 
Gal4dd) was incubated with Med15 as well as varying concentrations of Med15P and 
Med15DM.  Consistent with in vivo results, no interaction was observed between Gal4 
(1-100) and Med15.  However, introduction of the N342V mutation alone (Med15P) or in 
combination with the T322K (Med15DM) results in an interaction.  Although the limited 
solubility of the Med15 proteins prevented the determination of the complete binding 
isotherm, 18 µM Med15P or Med15DM was sufficient for about half of the Gal4 (1-
100)●DNA complex to form a ternary complex.  If the half maximal binding can be 
assumed to be representative of the KD for this interaction, it demonstrates the XLY has a 
higher affinity for Gal4dd than does Med15.  This data is also consistent with in vivo 





































Figure II-10: Electrophoretic mobility shift assays demonstrating interactions between 
DNA bound Gal4 (1-100) and mutants of Med15.  30 nM Gal4 was used in all 
experiments, a concentration sufficient for saturation of the 30bp DNA oligonucleotide 
used.  Concentrations in lanes 3,4,5, and 11 were 20 µM.  Concentrations of Med15P and 
Med15DM in lanes 6-10 and 12-16 were 1, 3, 9, 18, and 20 µM respectively. 
 
 
E.  Identification of the XLY Binding Site 
 Both the in vivo activation data as well as the in vitro binding data suggested an 
interaction between Gal4dd and XLY.  Two questions that remained were whether this 
interaction contributed to XLY function and where in the Gal4dd this interaction occurred. 
These questions were mainly addressed through a series of deletion and mutagenesis 
experiments carried out by our collaborators.  In the first set of experiments P201 was 
attached to the LexA DBD along with fragments of the Gal4dd.  As observed in Figure II-
11, no activation occurred until the entire dimerization domain of Gal4 (residues 50-100) 
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were present.  The last experiment in the figure demonstrates the importance of helix 1 
and loop 1, since constructs containing only helices 2 and 3 showed no activation. 
 
Figure II-11: A LexA-P201 chimera only activates transcription when the entire Gal4dd 
is also present. 
 
 In order to further refine the binding site, alanine scanning was performed.  Again 
the LexA DBD was used to prevent perturbation in Gal4 binding with the alanine scan in 
the dimerization domain.  This experiment demonstrates the importance of a number of 
residues in loop 1 of the dimerization domain, namely residues 68, 69, 72, and 75 (Figure 
II-12).  Mutations in these residues greatly diminished the P201 mediated activated 
transcription and is therefore the likely binding site of this peptide.  To further probe the 
importance of these residues, Steven Rowe expressed a mutant of Gal4dd containing the 
L69A mutation.  Indeed, this mutant did not interact with XLY, consistent with the in vivo 
results.   
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Figure II-12: a) Alanine scanning was used to uncover important residues for activation 
mediated by P201. b) Med15P and XLY target unique yet overlapping sites on Gal4dd. 
 
 We next compared the residues that were important for the Gal4dd●XLY 
interaction to those previously found to be critical for the Gal4dd●Med15P interaction.  
Some mutations, such as L86A and I89A, which completely disrupt the Gal4dd●Med15P 
interaction in vitro and activation in vivo, did not severely affect P201 mediated 
activation.  Others however, such as F68A, L77A, and D84A, completely abrogate P201 
mediated transcription yet do not affect the Gal4dd●Med15P interaction.  Although there 
are a number of residues which, when mutated, disrupt both interactions, the differences 
indicate that P201 and Med15P bind to distinct, yet overlapping surfaces on Gal4dd. 
 
F.  Dynamics of Binding 
 In order to more fully characterize the XLY●Gal4dd and the XLY●Med15 
interactions, Steven Rowe and I measured the off-rates of XLY with fluorescence 
polarization for both complexes.  In these experiments, XLY was fluorescently labeled 







50 µM Gal4dd with 25 nM XLY and 10 nM XLY respectively).  Following incubation, a 
large excess of unlabeled XLY was titrated in.  This resulted in a decrease in polarization 
as the fluorescently labeled bound peptide was competed off with the unlabeled peptide.  
As indicated in figure II-13, the dissociation of XLY was significantly faster with Gal4dd 
(0.24 s-1) than with Med15 (0.063 s-1).  In fact, the dissociation with Gal4dd was so fast, 
that nearly all of the peptide had been competed off before our first measurement was 
taken, thus the calculated koff for XLY●Gal4dd actually represents the lower limit of this 
rate.  In contrast, previous NMR measurements have shown the koff for Gal4dd●Med15P 
to be >5 s-1.  Although these measurements are not completely comparable since they 
were taken with different experimental techniques, the off-rate of Med15P from Gal4dd 
appears to be much faster that of XLY from Gal4dd.  This would help explain how XLY is 
capable of interfering with Gal4dd activation in yeast strains bearing Med15DM. 
 
Figure II-13: Fluorescence polarization was used to determine the dissociation rates of 
XLY for Gal4dd and Med15. 
 
koff 0.063 ± .022 s-1  koff 0.24 ± .026 s-1  
XLY + Gal4dd  XLY + Med15  
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G.  Model of P201 Function 
 Both the in vivo and in vitro data suggest that XLY is capable of making transient 
interactions with both Gal4dd as well as Med15.  This feature of transient concealment is 
commonly observed in endogenous activators, where hydrophobic residues critical for 
activation are often bound in intra- or intermolecular complexes preventing activation.  
When a gene product is needed, intracellular signals lead to the dissociation of this 
complex allowing transcriptional activation.19-21  One such example can be observed with 
the Gal4 activator.  In the absence of galactose, Gal4 is bound in a complex with the 
protein Gal80, preventing expression of the galactose metabolism genes.  However, in the 
presence of galactose, Gal3 binds to Gal80, causing a conformational allowing Gal4 to 
upregulate transcription.  Intramolecular examples of this type of ‘masking’ interaction 
also exist.  This is seen with the yeast proteins Leu3 and Put3 which control amino acid 
metabolism.21,22  In both cases, the full length protein is found to be inactive in vitro and 
in vivo due to masking.  It is only the presence of a specific metabolite that the AD is 
revealed and stimulation of gene expression is observed.  In both of these examples, 
another surface has co-evolved to bind and conceal the activating region.   
 Our data suggests a similar intramolecular binding interaction occurs with Gal4(1-
100)-P201, albeit without a cellular signal, leading to its remarkable potency.  Gal4(1-
100)-P201 likely exists in two conformations (Figure II-14).  In the “closed” 
conformation, XLY binds to the hydrophobic surface of loop one on Gal4dd, preventing 
non-productive interactions and likely preventing premature degradation.  In the “open” 
conformation, P201 binds to Med15 recruiting the RNA polymerase holoenzyme and 
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Figure II-14: Transient exposure of P201 leads to its remarkable activity in vivo. 
 
 
H. Masking Interactions and Potency 
 Many activators interact with masking proteins to prevent activation except in the 
presence of a cellular signal.  This allows the cell to maintain strict control over levels of 
gene expression.  On the other hand, artificial activators typically operate outside of this 
regulatory network and lack inter- or intramolecular masking within the cell.  While it 
was previously believed that these interactions were largely a mechanism of regulating 
transcription, Gal4(1-100)-P201demonstrates the important contributions these 
interactions can have on functional potency.   
 This property has also shown application in the construction of activator ATFs.  
Many of the inactive ligands from the Med15 screen contained hydrophobic amino acids 
in the randomized positions.  It was therefore likely that the incorporation of an 
intramolecular binding surface would prevent nonproductive interactions and stabilize the 
activator in the cell.  Two graduate students in my lab (Jenifer Lum and Chinmay 
Majmudar) tested these ligands in the context of Gal4(1-100).  In an analogous manner to 
Med15 
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Gal4(1-100)-P201, these inactive ligands were converted into potent transcriptional 
activators.  Further studies also demonstrated binding between these ligands and Gal4dd, 
indicating a similar interaction as observed with P201.23 
 
I. Experimental Details 
General peptide synthesis methods 
 Solid phase peptide synthesis was accomplished with FMOC-protected amino 
acids, HOBt, and HBTU purchased from Peptides International using standard methods 
either manually or using an Advanced ChemTech90 synthesizer using established 
protocols.   Peptide-synthesis grade DMF, Triethylamine, and piperidine were purchased 
from Fisher and used without further purification.  Coupling efficiencies were monitored 
using a ninhydrin test kit purchased from Fluka.  All peptides were purified to 
homogeneity using reversed-phase HPLC on a C18 column with a gradient solvent 
system (buffer A: 0.1% TFA, buffer B: CH3CN). 
 
β-Galactosidase Assays 
 β-Galactosidase assays were performed in LS41 [JPY9::ZZ41, Matα his3Δ200 
leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 gal4Δ11/ ZZ41] which was generously provided by 
Dr. Aseem Ansari (University of Wisconsin).  LS41 yeast was initially transformed with 
the expression vectors by Garrette Belanger using the Lithium Acetate method and plated 
on agar plates with the appropriate selection.  Single colonies were then chosen to 
inoculate 5 mL starter cultures which were grown for 12-18 hours at 30ºC in SC media 
containing 2% Raffinose.  The density of these cultures were then determined using 
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OD600 and they were then diluted to a concentration of 0.7 X 107 cells/mL in selection 
media supplemented with 2% Raffinose and 2% Galactose.  These cultures were then 
grown for 12-18 hours at 30ºC until the OD600 of the 10X dilution was between 0.4-0.7.  
Cells were harvested by centrifugation at 5000 RPM for 10 minutes at 4ºC.  Next, the 
cells were washed with 500 µL of sterile H20 and again harvested at 5000 RPM for 10 
minutes at 4ºC.  Following the wash, the cells were resuspended in 150-250 µL of 
Breaking Buffer (100 mM Tris-Cl pH 8.0, 20% glycerol, Roche protease inhibitor 
cocktail) and placed in an eppendorf tube.  In order to lyse the cells, glass beads were 
added and the cells were vortexed at maximum speed at 4ºC for one minute followed by a 
one minute break.  This process was repeated ten times to assure cell lysis.  In order 
remove the lysed cells, a needle was heated in a flame and used to pierce the bottom of 
the eppendorf tube.  This was then placed in a second tube and centrifuged for one 
minute at 4ºC.  The cellular debris was then pelleted by centrifuging at 14,000 RPM for 
ten minutes at 4ºC.  The clarified lysate was then transferred to a fresh tube and briefly 
vortexed to mix contents. 
 In order to determine the activity of the β-Galactosidase, 10-100 µL of lysate was 
diluted to 1 mL in Z-Buffer (40 mM Na2HPO4, 60 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, 50 mM 2-Mercaptoethanol).  These samples were then incubated at 30ºC for 30 
minutes.  Following incubation, 200 µL of ONPG (4 mg/mL in Z buffrer) was added to 
each sample and timed.  Once the samples began to turn yellow, the reactions were 
quenched with the addition of 500 µL of 1M Na2CO3 and the time was recorded.  The 
OD 420 was then determined for each sample.  In order to normalize each assay, the total 
protein concentration was measured with a Bradford Assay.  The activity of each sample 
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was then calculated with the equation: (OD420 * VT) / (P * VS * t * 0.0045) where VT is 
the total volume in mL, P is the total protein concentration in mg/mL, VS is the volume of 
lysate added, and t is the time before quenching.  The fold activities of each were 
determined by dividing the activity of a sample with the activity observed with the DBD 
alone.  All experiments were performed in triplicate with the standard deviation of the 
mean indicated. 
 
Synthesis of Fluorescein Labeled Gal11 Ligands 
 The Gal11 ligands were synthesized on Rink amide resin and a cysteine residue 
was incorporated at the carboxy terminus for subsequent functionalization. The peptides 
were then labeled on resin with fluorescein-5-maleimide (Molecular Probes).   At the 
conclusion of the synthesis, the peptides were fully deprotected and cleaved from the 
resin with treatment with 95% TFA/2.5% TIS/2.5% H2O, precipitated with cold ether, 
and purified to homogeneity using reversed-phase HPLC. Each peptide was characterized 
using electrospray mass spectrometry.  
 
Synthesis of Fluorescein Labeled XLY and XLR 
XLY and XLR were also synthesized on Rink amide resin.  Following the final Fmoc 
deprotection, the N-terminal amine was labeled with the succinimidyl ester of 
carboxyfluorescein (Molecular Probes).  The peptides were then cleaved with 95% 




Expression and Purification of GST-Med15 (186-619) 
The plasmid pGEXVsh1 was transformed into chemically competent BL21(DE3) pLysE 
E. coli (Invitrogen) and cells were plated onto LB-agar plates supplemented with 
ampicillin (0.1 mg/mL) and chloramphenicol (0.034 mg/mL). Cultures (50 mL) from 
single colonies were grown overnight at 37° C (275 rpm) in LB supplemented with 
ampicillin (0.1 mg/mL) and chloramphenicol (0.034 mg/mL) before addition to 1L of LB 
supplemented with ampicillin (0.1 mg/mL). After 3 h, the cultures were cooled to 16 °C, 
and expression was induced with IPTG (final concentration 0.5 mM) for 5 h. The cell 
pellet was lysed using sonication, and the GST tagged protein was isolated from the cell 
lysate using glutathione-sepharose beads (Amersham-Pharmacia Biotech). Elution from 
the beads was accomplished with 50 mM Tris•HCl buffer (pH 8.0) containing 15 mM 
glutathione and 0.1% NP-40. The protein solution thus obtained was concentrated to ~20-
25 µM and the buffer exchanged to storage buffer (PBS, pH 7.4, 1 mM DTT, 10% 
glycerol (v/v), and 0.01% NP-40) using a Millipore Ultrafree centrifugal filter device.  
The protein solution was stored in 50 µL aliquots at –80 °C until needed. The protein 
concentration was measured using a Bradford assay (Bio-Rad) with BSA as the standard. 
The identity and purity of the fusion protein was verified by reducing SDS-PAGE with 
appropriate molecular weight standards. 
 
Dissociation Constant Measurements 
 The dissociation constants of XLY and XLR for GST-Med15(186-619), GST-
Med15P(186-619), GST-Med15DM(186-619), GST-Gal4(52-100), and GST-Gal4(52-
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100) +P201 were determined by fluorescence polarization on a Spex Fluoromax-2 
fluorimeter.  All measurements on the Spex Fluoromax-2 were done at room temperature. 
 For each experiment, an aliquot of fluorescein-labelled peptide was dissolved in 
1mL of storage buffer (PBS, pH 7.4, 1 mM DTT, 10% glycerol (v/v), and 0.01% NP-40) 
and the concentration determined on a Varian Cary 300 Bio UV-Vis spectrophotometer.  
1.25 µM and 25 nM (for Med15 derivatives) or 10nM (for Gal4 derivatives) stocks of the 
labeled ligands in storage buffer were prepared.  For each experiment on the Spex 
Fluoromax-2, the 1.25 µM stock solutions were then each diluted into three separate 
solutions in a Starna quartz sub-micro 40 mL 10 mm cell to yield a final concentration of 
25nM (for Med15 derivatives) and 10nM (for the Gal4 derivatives) labeled peptide and 
between 14 µM and 40 µM protein (depending on the identity of the specific protein in a 
given experiment).  All of the solutions were allowed to equilibrate for 10 minutes a 
room temperature prior to the first polarization measurement and all experiments were 
performed in triplicate. 
 Following determination of the polarization for each sample at their respective 
concentrations, each of the samples was diluted with 25 nM or 10 nM stock of labeled 
peptide such that the concentration of the labeled peptides remained constant throughout 
the course of the experiment.  The diluted solutions were also allowed to reach 
equilibrium for 10 minutes prior to measurement of polarization.  The process was 
repeated for all concentrations. 
 The data collected from these experiments were plotted in Origin 7.0.  The data 
were fit to the equation Y = (aX) / (b + X) + c (Where Y is the observed polarization at a 
given protein concentration X, a is the amplitude of the polarization change, b is the KD, 
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and c is the polarization of free ligand) using the Levenberg-Marquardt least squares 
method.  Errors for individual data points were calculated as the standard deviation of the 
mean (SDOM) from three individual experiments. 
 
koff Measurments 
 All koff measurements were performed on the PanVera Beacon 2000 fluorimeter 
with the instrument set at 25°C.  In one set of triplicate experiments, fluorescein-labelled 
XLY at a concentration of 25 nM in storage buffer was incubated with 18 mM GST-
Med15(186-619) for 10 minutes.  Several successive polarization readings were taken to 
confirm the system had reached equilibrium.  At that time, a 1700-fold excess of 
unlabeled XLY was added in a minimal amount of storage buffer.  Polarization readings 
were taken every 11.5 seconds to monitor the release of the labeled peptide from the 
protein.  An identical set of experiments was performed to determine the off-rate of XLY 
from Gal4dd, except the concentration of the labeled peptide was adjusted to 10 nM and 
the protein concentration was changed to 50 µM.  In addition, a set of control 
experiments was also carried out in which an identical volume of storage buffer was 
added to the equilibrated peptide-protein solutions to examine the effect of dilution on 
polarization.  The changes in polarization due to dilution were then subtracted from the 
overall change.  The data from these experiments were entered into Origin 7.0 and fit to a 
single phase exponential decay using the Levenberg-Marquardt least squares method.  
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A Small Molecule Transcriptional Activation Domain2 
 
A.  Background 
 The development of small molecules to perturb biological systems has typically 
depended on high affinity ligands for a specific binding site on a protein.  While this 
approach is quite successful in a case where a single, well-defined binding site influences 
function, many biological processes are carried out by protein complexes whose 
assembly and function are initiated through a combination of weaker interactions with 
functionally redundant binding surfaces.  In order to regulate these types of systems, 
small molecules must mimic the binding profile of their endogenous counterparts.  
 Transcriptional activation is an example of a system which is initiated by a 
network of low affinity interactions.  For example the KDs of transcriptional activators for 
their protein targets have generally been found to be in the low micromolar range.  This is 
likely an essential functional contributor as these proteins must mediate the assembly of 
the large transcriptional machinery complex onto DNA.1  In addition, several lines of 
evidence suggest AD binding sites within the transcriptional machinery are somewhat 
functionally redundant.  For example, ADs from VP16, Gcn4, and Gal4 target an 
                                                
2 Portions of this chapter were taken from Minter, A. R.; Brennan, B. B.; Mapp, A. K. Journal of the 
American Chemical Society 2004, 126, 10504-10505. and Buhrlage, S. J.; Brennan, B. B.; Minter, A. R.; 
Mapp, A. K. Journal of the American Chemical Society 2005, 127, 12456-12457.  The isoxazolidines in 
Figure III-2 and III-11 were synthesized by Aaron Minter and Sara Buhrlage and I carried out all of the 
transcription assays. 
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overlapping group of transcriptional machinery protein targets yet exhibit very little 
sequence homology outside of a general amphipathic composition.2,3   
 ADs are often composed of surreptitious repeats of 5-10 amino acid sequences 
and the minimal repeat can itself act as an activation domain when fused to a DBD.  This 
demonstrates that relatively short sequences are capable of interacting with coactivator 
targets, and through these interactions, upregulating transcription.4-6  One such minimal 
activation domain sequence which has been well studied both in vitro and in vivo is 
ATF14 (CGSDALDDFDLDML), a sequence derived from the viral coactivator VP16.7  
This minimal module thus serves as a useful guide for the design of small molecule ADs.   
 
B. Isoxazolidine Scaffold 
 ADs typically bind to coactivator proteins in shallow binding surfaces.  These 
binding surfaces are promiscuous in nature and often allow interactions with numerous 
different proteins which can present functionality in an amphipathic manner.1,8,9  Our 
strategy for the creation of a small molecule activation domain involves displaying 
functionality observed in endogenous activators on a small molecule scaffold.  We 
therefore needed a scaffold that had good solubility properties, displayed functionality in 
a three dimensional array, and could be obtained with relative synthetic ease.  Five-
membered heterocycles have been shown in the past to exhibit all of these properties.  
The heteroatom in the ring increases solubility, the constrained ring allows for three 
dimensional projections, and numerous synthetic strategies are available for their 
construction.   
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 Five-membered heterocyclic rings have also been used by other groups for the 
disruption of protein•protein interactions.  Perhaps the best example is a class of 
imidazoline compounds constructed by Liu and coworkers to disrupt the interaction 
between MDM2 and p53.10  Overexpression of MDM2 has been associated with 
numerous cancers due to its ability to inhibit the tumor suppressor activator p53.11  In 
disrupting this interaction, p53 is allowed to upregulate apoptotic genes and prevent 
uncontrolled growth.  These imidazoline molecules, termed the Nutlins, bind tightly to 
MDM2 in the p53 binding site and therefore block MDM2’s ability to mask the p53 
activator (Figure III-1).  Particularly relevant to our work, p53 forms a helix upon binding 
to MDM2, and it is this helix that is mimicked by the Nutlins and prevents the 
interaction.  In an analogous manner, amphipathic activation domains form helices upon 
binding to coactivators.  We therefore inferred that a five member heterocycle with 
appropriate functionality could generally mimic an amphipathic activation domain 
allowing it to interact with coactivator proteins an upregulate transcription when 
localized to DNA.   
 
Figure III-1:  Nutlin-3 was discovered through a screen of molecules which could 
disrupt the MDM2•p53 interaction.  Nutlin-3 binds to MDM2 through mimicking the 
helix in p53 responsible for binding (right). Figure Reprinted from (10) with permission. 
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 Key functional groups found in the minimal peptidic AD module ATF14 include 
phenyl, hydroxyl, carboxylic acid, and isobutyl moieties.12-15  In order to identify a 
minimal functional unit for a small molecule-based activation domain, a series of 
isoxazolidines were synthesized by another graduate student (Aaron Minter), in which 
these important groups were appended to an isoxazolidine.  In addition, each 
isoxazolidine was also coupled to methotrexate (Mtx) in order to localize it to DNA for 
testing as an AD.  Our initial target compounds are shown in Figure III-2. 
 
Figure III-2: Initial targeted isoxazolidines contained functionality often observed in 
endogenous ADs. 
 
 Isoxazolidine III-1 contains three hydrophobic groups (benzyl, allyl, and 
isobutyl) appended at the N2 and C3 positions, while isoxazolidines III-2, III-3, and III-
4 contain a combination of polar (hydroxyl and carboxylic acid) and hydrophobic (benzyl 
and isobutyl) functionalities at N2, C3, and C5.  The core of the isoxazolidines was 
obtained via a 1,3-dipolar cycloaddition, and the relative stereochemistry at C3 and C5 
was set with a Grignard addition to the key intermediate (Figure III-3).  Following the 
Grignard addition, alkylation of N2 allows introduction of the benzyl or carboxylic acid 
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at that position (Figure III-3).16-18  All the isoxazolidines were made as racemic mixtures.  
The final step of the synthesis of III-1-III-4 was hydrazone formation with methotrexate 
hydrazide, used to localize the isoxazolidines to DNA in the functional assay.  I then 
synthesized ATF14 through solid phase peptide synthesis and coupled it to Mtx for direct 
















Figure III-3: Retrosynthetic strategy used to prepare isoxazolidines 
 
C. Testing the Isoxazolidine Activation Domains 
 In order to determine if our small molecule ADs were capable of upregulating 
transcription, they had to be localized to DNA and transcription levels measured.  As 
previously mentioned, naturally occurring transcriptional activators are composed of both 
a DBD as well as an AD.  One possibility was to couple our small molecule directly to a 
protein DBD; however side reactions and purification steps make this a very difficult 
option.  Alternatively, we decided to use a variation of a two-hybrid assay developed in 
the lab of Dr. Virginia Cornish at Columbia University.19   
 Traditionally, a two hybrid assay is used to determine if two proteins interact.  
Typically, Protein A is coupled to a DBD and Protein B is coupled to an AD.  If Protein 
A and Protein B interact with each other, a complete activator is reconstituted and 
activation is observed in a reporter gene with binding sites for the DBD.  In our case, the 
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first hybrid protein was composed of a fusion between the bacterial DBD of LexA and E. 
coli dihydrofolate reductase (eDHFR).19  The second hybrid in our case was not a protein, 
but instead a fusion between the small molecule methotrexate and our isoxazolidines.  
Methotrexate is an inhibitor of eDHFR with a KD of approximately 1 nM.20  Since the 
isoxazolidine is covalently linked to methotrexate and methotrexate binds to eDHFR 
which is expressed as a fusion protein with the LexA DBD, the isoxazolidine is localized 




Figure III-4: A diagram demonstrating the method of localizing an activation domain to 
DNA in a “two-hybrid” type manner.  The DBD of LexA (blue) is expressed as a fusion 
protein with bacterial DHFR (gray).  This protein binds to DNA bearing LexA binding 
sites.  Any molecule covalently linked to methotrexate (Mtx) is therefore localized to 
DNA through the interaction of Mtx and DHFR. 
 
 The next question to address was the method of monitoring the RNA output.  
Typical methods of in vitro transcription involve the use of radioactive isotopes.21-23  
Generally, radiolabeled nucleotides are incorporated into an RNA transcript.  The 
transcript can then be run on a gel to separate the incorporated from the free radioactive 





Figure III-5: Radioactive in vitro transcription assay. 
Although the sensitivity of the radioactive assay makes it extremely valuable, there are 
some downfalls associated with it.  This process can tend to be quite labor intensive and 
requires multiple RNA handling steps.  Although we initially only had four compounds to 
test, the future plans involve testing libraries of small molecules as ADs.  Therefore, we 
needed to develop a more high-throughput assay capable of testing numerous compounds 
at once. 
 One method of monitoring small amounts of RNA with high specificity and 
sensitivity involves the use of molecular beacons.  Molecular beacons are hairpin 
oligonucleotides with a fluorophore on the 5’ end and a quencher on the 3’ end.24  They 
are designed such that when a hairpin forms, the fluorophore and quencher are in close 
spatial proximity.  Therefore, in this “closed” state, fluorescence intensity is low.  The 
molecular beacon also contains a loop sequence capable of binding to an RNA or DNA.  
This target oligonucleotide base pairs with the molecular beacon, disrupting the internal 
hairpin and converting it into an “open” form..  It is more energetically favorable for the 
beacon to form the 10-20 bp interaction with the target than it is for it to form the internal 
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hairpin.  In the open conformation, the distance between the fluorophore and quencher is 
increased leading to an increase in the amount of fluorescence observed. (Figure III-6).25 
 
Figure III-6: Molecular beacons are an RNA or DNA oligonucleotide capable of 
forming a hairpin labeled with a fluorophore (green circle) and a quencher (black circle) 
at the 5’ and 3’ ends.  Molecular beacons exist in two conformations.  In the absence of 
an RNA or DNA target, they form a hairpin, termed the “closed” conformation, and little 
fluorescence emission is observed.  However, in the presence of their oligonucleotide 
targets, the beacon converts into an “open” conformation and increased fluorescence is 
observed. 
 
Molecular beacons have proven useful in numerous applications.  The stability of the 
closed conformation allows them to have remarkable specificity for a target nucleic acid.  
Because of this, they can discriminate between a single mismatch and have been used to 
detect mutations.  In addition, the presence of a strong quencher greatly decreases the 
background fluorescence of the probe and therefore allows for a large dynamic range.26  
This has made them useful for observing mRNA in a single living cell and for in vitro 
transcription assays.23,27 
 All of these properties make the molecular beacon an attractive method for 
monitoring activation of transcription of the isoxazolidines.  In order to assure that 
fluorescence intensity could be observed at target levels expected in the assay (1-20 nM), 
a titration experiment was carried out.  In this experiment, increasing concentrations of 
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target or a mismatch oligonucleotide were added to a constant concentration of molecular 
beacon (100 nM) in transcription buffer (Figure III-7).  Over this concentration range, an 
increase in fluorescence intensity could be observed, confirming the usefulness of this 
method for measuring transcription.   
 
Figure III-7: Titration of complementary oligonucleotide with the molecular beacon 
resulted in a linear dose dependent increase in fluorescent signal. 
 
In addition to the use of this molecular beacon to monitor the levels of transcript, a 
second molecular beacon was used to normalize the background fluorescence of each 
sample.  This sequence of the second beacon is not complementary with the sequence of 
the transcript produced and thus should remain in the “closed” conformation.  The 
fluorophore on this beacon also fluoresces at a different wavelength and thus can by 
monitored in the presence of the first beacon.  
 
D. Results of Initial Compounds: 
 With the assay for measuring transcription in place, the individual isoxazolidines 
could be tested.  The plasmid used for measuring activation contained two LexA binding 
sites upstream of an AdML promoter.  Since LexA binds as a dimer, this resulted in four 
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isoxazolidines on each promoter.  Following incubation of the DNA template with LexA-
eDHFR and the small molecule, the transcription reaction was initiated by addition of 
HeLa nuclear extracts.  mRNA production was directly measured with the molecular 
beacon and used to determine the activity of all compounds, displayed as a percent 
activation relative to the positive control ATF14 (Figure III-8). 
 
Figure III-8: Results from in vitro transcription assays.  The activity of each compound 
represents the average of at least three individual experiments with the indicated error 
(SDOM). 
 
 Remarkably, isoxazolidine III-4 was as active as the positive control ATF14 
despite a considerable difference in size (MW 290 vs. 1674).  Further it was found to be 
the most potent of all the isoxazolidines tested, with 5-7 fold activation over basal 
transcription.  Similar to natural activation domains such as ATF14, a balance of 
hydrophobicity and polarity is important for overall potency.  Substantially increasing the 
hydrophobicity (III-1) or the polarity (III-2) led to a dramatic decrease in function.  In 
contrast, slightly increasing the polarity at C3 by the incorporation of an additional 
























 We next carried out experiments to further probe the mechanism of activation.  
The first of these examined the importance of localizing the small molecule to DNA.  In 
order to address this, Aaron Minter synthesized a version of III-4 without methotrexate 
attached, and thus would not bind to the protein DBD.  As expected, the acetal version of 
the active compound (III-5) was unable to upregulate transcription, demonstrating the 
requirement for localization to DNA (Figure III-9a).  Further, a competitive inhibition 
experiment was carried out in which an excess of (III-5) was added in the presence of the 
active compound.  Competitive inhibition experiments with endogenous activators 
typically result in inhibition of transcription due to titration of activator binding sites 
within the transcriptional machinery.28  In an analogous manner, the addition of 1 µM 
III-5 inhibited the ability of III-4 to activate transcription (Figure III-9b).  In concert, 
these results suggest a mechanism of function in which the DNA bound isoxazolidine 
















































Figure III-9:  (a) Activation by the isoxazolidine is dependent on localization to DNA.  
(b) Addition of 1 µM free isoxazolidine (III-5) inhibits activation of III-4, likely through 
titration of coactivator binding sites. 
 
E.  Conclusions from Initial Studies 
 Two factors likely play a role in isoxazolidine III-4 being nearly as active as 
ATF14 despite the size difference.  As an organic molecule, III-4 is resistant to 
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proteolytic degradation and thus probably has a longer lifetime in the transcription assay.  
In addition, structural studies suggest that while many natural activation domains are 
unstructured in solution, helix formation often accompanies activator●target interactions.  
In contrast, III-4 likely populates conformations more closely related to the bound state 
due to structural constraints imposed by the ring.  Both factors should also contribute to 
the function of III-4 in cells and will be discussed in detail in Chapter IV.  Furthermore, 
when sequences of minimal modules such as ATF14 are reiterated to make longer 
activation domains, the levels of transcription elicited increase synergistically.  Thus 
considering III-4 as a minimal functional module, it would be expected that oligomers of 
this isoxazolidine should exhibit increased potency.  This represents the first example of a 
small molecule transcriptional activation domain and is a valuable tool for studying the 
mechanistic details of eukaryotic transcriptional activation. 
 
F.  Stereochemical Promiscuity in Artificial Transcriptional Activators 
 Endogenous activators target an overlapping set of coactivators despite little 
sequence homology, suggesting permissive binding sites.  Further support of the 
permissive nature of coactivator binding sites was demonstrated by Verdine and 
Coworkers in a series of experiments carried out on a derivative of the activation domain 
of VP16.29  In these experiments, Verdine used a modified two hybrid assay in order to 
determine if the enantiomer of the VP16 derived activation module ATF29 could 
upregulate transcription in vitro and in cell culture (Figure III-10a).  If the binding sites 
for this AD were specific for the natural L version of the peptidic activator, one would 




Figure III-10: a) The L and D versions of ATF29 were coupled to FK506 in order to 
localize them to DNA and test for activation.  b) The natural L-version of the peptide, 
labeled L-1, and the unnatural D-version, labeled D-1, activated transcription in vitro 
only when coupled to FK506, demonstrating the need for DNA localization.  c) Only D-1 
activated transcription in cell culture, likely due to its proteolytic stability. Furthermore, 
activation is abolished in the presence of rapamycin, a compound which inhibits the 
interaction between FK506 and FKBP. Figure from (29). 
 
As demonstrated in Figure III-10, both the L and D peptide activated transcription in 
vitro while only the D peptide activated transcription in cells.  The latter result is likely 
due to proteolytic stability of the D peptide in cells as compared to the L version.  
Evidently, specific placement of functionality does not appear to be critical for the 
function of endogenous activators.  In order to see if this was also the case for our small 
molecule activation domain, we decided to carry out a positional “mutagenesis” 
experiment.30  Different analogues of III-4, our most active small molecule, were 
evaluated in which identical side chains were placed in various positions within the 
isoxazolidine scaffold.  In our original experiments, all isoxazolidines were prepared as 
racemates and were tested as stereoisomeric mixtures.  Sarah Buhrlage and Aaron Minter, 
fellow graduate students in the lab, therefore synthesized each enantiomer of III-4 (III-
4a and III-4b), as well as a diasteriomer (III-6), and two positional isomers (III-7 and 






Figure III-11: Compounds used for positional “mutagenesis” study.  Hydrophobic side 
chains of the isoxazolidine are colored green and polar side chains are red.   
 
All compounds contain the same functional groups found in the original active compound 
(III-4) but in varying three dimensional orientations.  Analogous to endogenous 
activators, we hypothesized that all molecules would function as ADs.  Testing of the 
molecules was done in an identical manner as earlier described and the activity of each 
compound was compared to that of ATF14, our positive control.   
 We observed that the activities of the enantiomers III-4a and III-4b are 
indistinguishable from that of AD III-4 containing a mixture of the two (Figure III-12).  
Isoxazolidines III-6, III-7, and III-8 differed more significantly in the presentation of the 
amphipathic functional groups due to stereochemical changes (III-6) or positional 
changes (III-7 and III-8).  However, in line with our hypothesis, all function well as 


























Figure III-12: Results from in vitro transcription assays of positional “mutants”. 
 
 
 The conserved activity across isoxazolidines III-4, III-4a, III-4b, III-6, III-7, 
and III-8 parallels the functional behavior of the endogenous amphipathic ADs that this 
molecular class was designed to mimic.  For example III-4a and III-4b each activate 
transcription to similar levels, which was also observed with L and D ATF29 peptides 
previously discussed.29  Among peptidic ADs, a variety of combinations of polar and 
hydrophobic amino acids function as ADs, but a hydrophobic/polar balance is 
conserved.1,8,31 Like our small molecules, endogenous ADs share a common structural 
motif.  Helix formation often accompanies binding of endogenous ADs to their protein 
targets.32-34  Also similar to the isoxazolidines, mutations in natural ADs that disrupt the 
hydrophobic surface greatly impact potency.6,35,36  Another remaining question is whether 
the isoxazolidines target similar binding surfaces as their endogenous counterparts.  
While this question remains to be fully answered, it will be addressed in more detail in 
Chapter IV.  Overall, however, these data suggest that isoxazolidines are unlikely to be 
the only suitable scaffolds for the construction of small molecule ADs.  Rather, a variety 
of appropriately functionalized, conformationally constrained small molecules should 
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function as well.  While this hypothesis is not directly addressed in this work, it is a 
matter of ongoing investigation by other graduate students in the Mapp lab.  This strategy 
obviates the need to identify high affinity ligands for a single protein target and takes 
advantage of the remarkable functional flexibility of the endogenous regulatory system.   
 
G. Experimental Details 
Synthesis of ATF14 
 The well-characterized activator ATF14 was used as the positive control in all in 
vitro transcription experiments.  Solid phase peptide synthesis was accomplished with 
FMOC-protected amino acids, HOBt, and HBTU purchased from Peptides International 
using an Advanced ChemTech90 synthesizer using established protocols. Peptide-
synthesis grade DMF, triethylamine, and morpholine were purchased from Fisher and 
used without further purification.  Coupling efficiencies were monitored using a 
ninhydrin test kit (Fluka).  Next, the protected peptide on solid phase was coupled to the 
γ-carboxylate of methotrexate using HOBt, HBTU, and triethylamine in DMF.  Cleavage 
of the peptide from solid phase and deprotection was carried out in 95% TFA, 2.5% H2O, 
and 2.5% triisopropylsilane.  Methotrexate-coupled ATF14 was purified to homogeneity 
using reverse-phase HPLC on a C18 column with a gradient solvent system (buffer A: 
0.1% TFA, buffer B: CH3CN).  Lastly, characterization was carried out using ESI-MS 
and UV-vis spectroscopy.  UV (λmax nm) 260, 306, 373; ESI-MS calculated for [Mtx-




General molecular biology methods 
 HeLa nuclear extracts, nucleotide triphosphates, and MgCl2 were purchased from 
Promega and used in accordance with manufacturer instructions.  Restriction 
endonucleases and T4 DNA Ligase were purchased from New England Biolabs and used 
as directed.  Oligonucleotides, DH5α  E. coli, and BL21(DE3) pLysE E. coli used for 
plasmid construction, amplification, and protein expression were obtained from 
Invitrogen. Molecular beacons were purchased from Biosearch Technologies.  The 
plasmid encoding LexA-eDHFR (pWA02) was generously provided by Dr. Virginia 
Cornish (Columbia University). All other chemicals and supplies were purchased from 
Fisher unless otherwise noted.   
 
Template construction 
 The DNA template for in vitro transcription was constructed from the pUC18 
plasmid.  First, the AdML promoter was inserted into the plasmid by annealing the 
oligonucleotides (5’ - AGC TTT GAG GAC GAA CGC GCC CCC ACC CCC TTT TAT 
AGC CCC CCT TCA GGA ACA CCT GAG CCG ATT GCT GGC GAT CAA CGC 
GTA AAG CCG ATA GCC GAC - 3’) and (5’- CTA GGT CGG CTA TCG GCT TTA 
CGC GTT GAT CGC CAG CAA TCG GCT CAG GTG TTC CTG AAG GGG GGC 
TAT AAA AGG GGG TGG GGG CGC GTT CGT CCT CAA - 3’) producing sticky 
ends that could be cloned into pUC18 following a double digestion with HindIII and 
XbaI. Next the LexA binding sites were inserted 60 base pairs from the TATA box by 
annealing (5’ – GAT CCA CTG CTG TAT ATA AAA CCA GTG GTT ATA TGT ACA 
GTA GAC TGC TGT ATA TAA AAC CAG TGG TTA TAT GTA CAG TAG AGA 
 69 
TCT T – 3’) and (5’ – AAT TAA GAT TCC TAC TGT ACA TAT AAC CAC TGG TTT 
TAT ATA CAG CAG TCT ACT GTA CAT ATA ACC ACT GTT TTT ATA TAC AGC 
AGT G – 3’) producing sticky ends that could be cloned into the AdML containing 
pUC18 plasmid following its digestion with BamHI and EcoRI. Lastly, the molecular 
beacon compliment was inserted by annealing (5’- TAT GAA AAA AAG TTA AGA 
CCT ATG CTC GCT - 3’) and (5’GCG CAG CGA GCA TAG GTC TTA ACT TTT 
TTT CA – 3’) producing sticky ends that could be inserted into the LexA and AdML 
containing plasmid following its digestion with KasI and NdeI.  All intermediate and final 
plasmids were amplified in DH5α E. coli, selected on LB-agar plates containing 0.1 
mg/mL ampicillin, and isolated from cultures using a QIAprep Spin Miniprep Kit 
(Qiagen).  The sequences of the isolated plasmids were verified by sequencing at the 
University of Michigan Core Facility. 
 
LexA-eDHFR expression and purification 
 The LexA-eDHFR plasmid pWA02 was transformed into chemically competent 
BL21(DE3) pLysE E. coli (Invitrogen) and cells were plated onto LB-agar plates 
supplemented with ampicillin (0.1 mg/mL) and chloramphenicol (0.034 mg/mL). 
Cultures (50 mL) from single colonies were grown overnight at 37 °C (275 rpm) in LB 
supplemented with ampicillin (0.1 mg/mL) and chloramphenicol (0.034 mg/mL) before 
addition to 1L of LB supplemented with ampicillin (0.1 mg/mL).  After 3 h, the cultures 
were cooled to 16 °C, and expression was induced with IPTG (final concentration 0.5 
mM) for 5 h.  Cells were harvested through centrifugation at 4 °C and 5000 RPM for 20 
minutes.  The cell pellet was resuspended in lysis buffer (50 mM NaH2PO4 (pH 8.0), 300 
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mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, and 10% glycerol), lysed using 
sonication, and the His tagged protein was isolated from the cell lysate using Ni2+ 
charged agarose beads (Qiagen).  The resin-bound protein was then washed with lysis 
buffer supplemented with 20 mM imidazole and eluted with lysis buffer supplemented 
with 250 mM imidazole.  Storage buffer (40 mM Tris (pH 7.8), 100 mM KCl, 0.2 mM 
EDTA, 0.5 mM PMSF, 0.5 mM DTT, and 25% glycerol) was then exchanged with the 
lysis buffer with the use of an Amicon® Ultra-4 centrifugal filter unit with a NMWL of 
5,000 Da (Millipore).  Lastly, the protein was snap frozen and stored at –78 °C in storage 
buffer.  Protein purity was determined through SDS-PAGE and protein concentration was 
measured using Bradford reagent (BioRad). 
 
In vitro transcription 
 
 The in vitro transcription reactions were monitored with molecular beacons and 
accomplished using standard protocols. For each reaction, 100 ng of template DNA was 
incubated with 50 nM LexA-eDHFR and 50 nM activator or negative control in a buffer 
containing 5 mM MgCl2, 400 µM of each NTP, 10 µg of salmon sperm carrier DNA, 10 
mM HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 0.25 mM DTT, and 10% glycerol in 
50 µL at 30 °C.  All reactions were initiated by the addition of 8 units of HeLa nuclear 
extracts and were incubated at 30 °C for 60 min. Following the 60 min incubation, the 
reaction was terminated by the addition of NaCl at a final concentration of 500 mM.  
Molecular beacon was added in simultaneously at a concentration of 100 nM.  
Fluorescence signal was measured on a SpexFluoromax-2 with excitation and emission 
wavelengths at 492 nm and 520 nm respectively. An internal standard consisting of a 
mismatch molecular beacon with a Quasar 670 fluorophore (λex = 649, λem = 670) was 
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also added to each reaction.  Fluorescence intensity at 520 nm was divided by intensity at 
670 nm to give a normalized intensity.  To obtain fold activation, each individual 
experiment was divided by the average of two controls reactions containing methotrexate 
hydrazide.   For Figure III-8 and III-12, the fold activities were converted to percent 
activation relative to the activity of ATF14. 
 
H.  References 
 
 (1) Ptashne, M.; Gann, A. Genes & Signals; Cold Spring Harbor Laboratory: 
New York, 2001. 
 (2) Melcher, K. Journal of Molecular Biology 2000, 301, 1097-1112. 
 (3) Brown, C. E.; Howe, L.; Sousa, K.; Alley, S. C.; Carrozza, M. J.; Tan, S.; 
Workman, J. L. Science 2001, 292, 2333-7. 
 (4) Wu, Y. B.; Reece, R. J.; Ptashne, M. Embo Journal 1996, 15, 3951-3963. 
 (5) Ohashi, Y.; Brickman, J. M.; Furman, E.; Middleton, B.; Carey, M. 
Molecular and Cellular Biology 1994, 14, 2731-2739. 
 (6) Drysdale, C. M.; Duenas, E.; Jackson, B. M.; Reusser, U.; Braus, G. H.; 
Hinnebusch, A. G. Molecular and Cellular Biology 1995, 15, 1220-1233. 
 (7) Stanojevic, D.; Young, R. A. Biochemistry 2002, 41, 7209-7216. 
 (8) Giniger, E.; Ptashne, M. Nature 1987, 330, 670-672. 
 (9) Ma, J.; Ptashne, M. Cell 1987, 51, 113-119. 
 (10) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; 
Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. 
Science 2004, 303, 844-848. 
 (11) Vogelstein, B.; Lane, D.; Levine, A. J. Nature 2000, 408, 307-310. 
 (12) Gerber, H. P.; Seipel, K.; Georgiev, O.; Hofferer, M.; Hug, M.; Rusconi, 
S.; Schaffner, W. Science 1994, 263, 808-811. 
 (13) Courey, A. J.; Holtzman, D. A.; Jackson, S. P.; Tjian, R. Cell 1989, 59, 
827-836. 
 (14) Courey, A. J.; Tjian, R. Cell 1988, 55, 887-898. 
 72 
 (15) Mermod, N.; Oneill, E. A.; Kelly, T. J.; Tjian, R. Cell 1989, 58, 741-753. 
 (16) Fuller, A. A.; Chen, B.; Minter, A. R.; Mapp, A. K. Journal of the 
American Chemical Society 2005, 127, 5376-5383. 
 (17) Minter, A. R.; Brennan, B. B.; Mapp, A. K. Journal of the American 
Chemical Society 2004, 126, 10504-10505. 
 (18) Minter, A. R.; Fuller, A. A.; Mapp, A. K. Journal of the American 
Chemical Society 2003, 125, 6846-6847. 
 (19) Baker, K.; Bleczinski, C.; Lin, H.; Salazar-Jimenez, G.; Sengupta, D.; 
Krane, S.; Cornish, V. W. Proc Natl Acad Sci U S A 2002, 99, 16537-42. 
 (20) Sasso, S. P.; Gilli, R. M.; Sari, J. C.; Rimet, O. S.; Briand, C. M. Biochim 
Biophys Acta 1994, 1207, 74-9. 
 (21) Lue, N. F.; Flanagan, P. M.; Kelleher, R. J.; Edwards, A. M.; Kornberg, R. 
D. Methods in Enzymology 1991, 194, 545-550. 
 (22) Lee, D. C.; Roeder, R. G. Mol Cell Biol 1981, 1, 635-51. 
 (23) Liu, J.; Feldman, P.; Chung, T. D. Anal Biochem 2002, 300, 40-5. 
 (24) Tyagi, S., Fred Russell Kramer Nature Biotechnology 1996, 14, 303308. 
 (25) Bonnet, G.; Tyagi, S.; Libchaber, A.; Kramer, F. R. Proc Natl Acad Sci U 
S A 1999, 96, 6171-6. 
 (26) Bratu, D. P. Methods Mol Biol 2006, 319, 1-14. 
 (27) Peng, X. H.; Cao, Z. H.; Xia, J. T.; Carlson, G. W.; Lewis, M. M.; Wood, 
W. C.; Yang, L. Cancer Res 2005, 65, 1909-17. 
 (28) Gill, G.; Ptashne, M. Nature 1988, 334, 721-724. 
 (29) Nyanguile, O.; Uesugi, M.; Austin, D. J.; Verdine, G. L. Proceedings of 
the National Academy of Sciences of the United States of America 1997, 94, 13402-
13406. 
 (30) Buhrlage, S. J.; Brennan, B. B.; Minter, A. R.; Mapp, A. K. Journal of the 
American Chemical Society 2005, 127, 12456-12457. 
 (31) Ma, J.; Ptashne, M. Cell 1987, 48, 847-853. 
 (32) Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, 
A. J.; Pavletich, N. P. Science 1996, 274, 948-953. 
 73 
 (33) Radhakrishnan, I.; Perez-Alvarado, G. C.; Parker, D.; Dyson, H. J.; 
Montminy, M. R.; Wright, P. E. J. Mol. Biol 1999, 287, 859–865. 
 (34) Parker, D.; Jhala, U. S.; Radhakrishnan, I.; Yaffe, M. B.; Reyes, C.; 
Shulman, A. I.; Cantley, L. C.; Wright, P. E.; Montminy, M. Molecular Cell 1998, 2, 
353-359. 
 (35) Regier, J. L.; Shen, F.; Triezenberg, S. J. Proceedings of the National 
Academy of Sciences of the United States of America 1993, 90, 883-887. 
 (36) Uesugi, M.; Verdine, G. L. Proceedings of the National Academy of 





Small Molecule Activation in Living Cells and Insights into their Cellular 
Mechanism of Action3 
 
A. Background 
 The ability to perturb biological processes with small molecules in living cells 
presents many challenges not present in a cell-free assay.  Factors such as cell 
permeability, nuclear localization, and cellular stability can often have dramatic effects 
on function.1  Thus, the activity observed with the isoxazolidines in the cell-free assay 
does not necessarily translate to activity in cells.  For example, the small molecule 
activation domain wrenchnolol (Figure IV-1) developed by Uesugi demonstrated modest 
activity in vitro but failed to activate transcription in cells.  Fluorescence microscopy 
experiments suggested this was the result of poor cell permeability characteristics.1 
                                                
3 Portions of this chapter were taken from Rowe, S. P..; Casey, R. J.; Brennan, B. B.; Buhrlage, S. J.; Mapp, 
A.K. Transcriptional Upregulation in Cells Mediated by a Small Molecule 2007 J. Am. Chem. Soc. 
accepted. The experiments represented by Figure IV-5 and IV-6 were performed by Steven Rowe.  I 
performed the experiments represented by Figure IV-2, IV-9, IV-11, IV-12, IV-13, and IV-14.  Compounds 
IV-1 and IV-2 were synthesized by Ryan Casey and coupled to OxDex by Steve Rowe.  The polyamide 





Figure IV-1:  A wrenchnolol polyamide conjugate activates transcription in a cell-free 
system.  The fluorescent label was attached in order to monitor cell permeability.1 
 
 
A cell-free system also contains a much more limited range of binding partners.  This is 
an important factor with ADs considering their promiscuous binding profile.2  The 
transition from cell-free activity to cellular function can therefore be quite challenging, 
illustrated by the complete absence of cellularly active small molecule ADs identified to 
date.  In this Chapter, we demonstrate that the isoxazolidine ADs function in both S. 
cerevisiae and human cells.  Further, the use of cross interference experiments with 
isoxazolidines provides evidence of overlapping coactivator targets with an endogenous 
AD. 
 
B.  Cellular Activity in Saccharomyces cerevisiae 
 We chose to initially assess the cellular activity of the small molecules in yeast 
because the DNA binding strategy used in the cell-free system functions well in S. 
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cerevisiae; methotrexate conjugates cannot be used in mammalian cells due to toxicity.3  
There is significant conservation of the transcriptional machinery across eukaryotes and 
we therefore anticipated that the activity observed with mammalian nuclear extracts 
would also be seen in yeast as long as the small molecule was capable of transporting to 
the nucleus.4-6  Since a number of methotrexate derivatives of comparable size have been 
shown to be cell permeable in yeast, we also anticipated permeability with our small 
molecule ADs.7,8 
 The positive control used in this assay was the peptide ATF14 coupled to 
methotrexate, the same as in our cell-free system.  It was anticipated that due to the large 
size and potential proteolytic instability of this molecule that other positive controls 
would need to be used in the long term.  In order to assess the cellular activity of III-4 an 
assay was carried out in V784Y yeast, a strain harboring the LexA-eDHFR expression 
vector as well as an integrated β-galactosidase reporter gene with eight LexA binding 
sites 234 bp upstream of the transcription start site provided by Dr. Virginia Cornish.  
The methotrexate-isoxazolidine conjugates were dissolved in methanol and added to a 3 
mL yeast culture in SC media to a final concentration of 1 µM.  Following a 24 hour 
incubation at 30ºC, a quantitative β-galactosidase assay was performed to assay 





Figure IV-2: Activation of transcription by III-4 in a yeast cell-based assay.   All 
compounds were added to a final concentration of 1 µM.  Each experiment was 
performed in triplicate with the indicated error (SDOM). 
 
In this context, we observed a nearly two-fold activation of transcription from addition of 
III-4 to yeast cultures when compared to methotrexate alone, our negative control.  
Furthermore, the comparative activity between III-4 and ATF14 was very similar to what 
was observed in the cell free system, albeit with attenuated overall levels of transcription.   
 One possibility for the levels of activation observed could be the stability of the 
compound in cells.  As previously mentioned, a hydrazone linkage was used to couple 
methotrexate to the isoxazolidine.  While this conjugate is likely stable over the short 
time course of the cell-free assay, hydrolysis in cells could partially or completely destroy 
this linkage.  Although a much more stable amide bond was used for coupling ATF14 to 
methotrexate, proteolysis within the cellular environment likely leads to the degradation 
of this peptide resulting in the observed low levels of activation observed.  In addition to 





















C.  Activity in HeLa Cells 
 Since the majority of the applications envisioned for the isoxazolidine ADs would 
be in human cells, we chose to investigate the activity in this context rather than 
optimizing activity in S. cerevisiae.  As previously mentioned, the toxicity of 
methotrexate prevents its use in human cells, therefore a different DBD strategy is 
needed.  We decided to utilize an analogous two-hybrid assay developed by the Kodadek 
group in which a fusion of the DBD Gal4(1-147) and the minimal ligand binding domain 
of the human glucocortocoid receptor (hGR) (499-777) is used to localize molecules 
tagged with dexamethasone (an hGR ligand) to Gal4-binding sites at a promoter on a 
reporter vector (Figure IV-3).9   
 
 
Figure IV-3: Method of localizing the isoxazolidines to DNA in the mammalian cell 
assay.  OxDex represents an oxidized version of the steroid dexamethasone, GR LBD 
represents the minimal glucocortocoid ligand binding domain, and Gal4 DBD represents 
the Gal4 DNA binding domain. 
 
For this assay, it was necessary to prepare isoxazolidine derivatives attached to a 
modified version of dexamethasone (OxDex) (Figure IV-4).  Ryan Casey, Sara Buhrlage 
and Steven Rowe synthesized the new isoxazolidine constructs and Steven and I tested 
them for transcriptional activation.   
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Figure IV-4: OxDex conjugated isoxazolidines tested in the mammalian cell assay. 
 
 A dual luciferase assay was used in order to determine the levels of transcription 
elicited by our small molecules.  Prior to addition of the small molecule-OxDex 
conjugates, HeLa cells were plated on 96-well plates and cotransfected with three 
plasmids.  The first plasmid encoded the gene for a constitutively expressed fusion 
protein, Gal4 DBD-hGR LBD, the second ecoded a gene expressing Firefly luciferase 
with five Gal4 binding sites upstream of the transcription start site, and the third encoded 
the gene for a constitutively expressed Renilla luciferase.  Both Firefly and Renilla 
luciferase can be independently measured, which allows the use of Renilla luciferase as 
an internal transfection control to normalize against variations in transfection efficiency. 
 Following transfection, various concentrations of IV-1, IV-2, or IV-3 were added 
to the HeLa cells as a DMSO solution.  The final concentration of DMSO in all wells was 
1% (vol/vol).  In each case, the fold activation of transcription was determined by 
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dividing the luciferase activity of cells incubated with IV-1 or IV-2 by that of cells 
incubated with IV-3 at the indicated concentrations (Figure IV-5). 
 
 
Figure IV-5: Results from the luciferase assay in HeLa cell culture. 
As illustrated in figure IV-5, the amphipathic isoxazolidine (IV-1) exhibited measurable 
activity even at very low nanomolar concentrations (5-fold at 5 nM) and 80-fold activity 
at 1 µM.  Additionally, over the concentration range tested, no phenotypic changes were 
observed with the cells and expression of the Renilla luciferase transfection control 
remained unaffected.  Analogous to the cell-free data, IV-2 does not function as a 
transcriptional activation domain at concentrations up to 1 µM.  Similar to endogenous 
activators, the amphipathic characteristics of IV-1 are important for the overall activity of 
this small molecule AD. 
 The DBD and the AD of natural activators typically function in an independent 
manner.2  To test if the Gal4-hGR construct contributed to the activity observed with IV-




























nM) of IV-1 along with increasing concentrations of IV-4, the isoxazolidine that is not 
conjugated with OxDex, was added to a series of HeLa cells.  As illustrated in Figure IV-
6, at a concentration of 100 µM, transcriptional activation by IV-1 was inhibited by 
approximately 70% (.  These data are consistent with the DBD serving as an inert 
promoter localization scaffold.   
 
Figure IV-6: Activation by IV-1 is inhibited by the addition of IV-4. 
 
The isoxazolidine does require DNA localization in order to activate transcription as 
evidenced by the inability of IV-4 to function as a transcriptional activation domain at 
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Figure IV-7:  No activation is observed with the amphipathic isoxazolidine if it is not 
coupled to the OxDex DNA localization moiety. 
 
 This assay was initially developed by the Kodadek lab in order to discover 
peptoid ADs which could function in cell culture.  Their initial screen yielded one 
peptoid with extremely potent activity (Figure IV-8).9 
 
Figure IV-8:  KIX binding peptoid KBPo2.9 
Although this compound elicited nearly 900-fold activation at its maximal concentration, 
nearly 10 µM was needed to reach the EC50.  In order to more directly compare our 
amphipathic isoxazolidine activation domain (IV-1) with this peptoid, an assay was 
carried out over a larger concentration range and the EC50 calculated (Figure IV-9). 
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Figure IV-9: The EC50 of IV-1 is 36 nM.  HeLa Cells are incubated with various 
concentrations of IV-1 and then the fold activation is determined from the measured 
luciferase activity compared to that elicited by IV-3. 
 
As demonstrated in Figure IV-9, the EC50 of the amphipathic isoxazolidine (IV-1) is 
approximately 36 nM.  Remarkably, even at very low concentrations, IV-1 is capable of 
mediating protein•protein interactions necessary for transcriptional activation.  The 
decreased EC50 of IV-1 compared to KBPo2 is likely due to both enhanced cell 
permeability and the smaller size (1100 and 290 MW).  The observed activity at such low 
concentrations will certainly be advantageous as we move to more complicated systems, 
where cellular delivery is often the limiting factor to potency. 
 
D.  A Fully Synthetic Activator ATF 
 One advantage to using the Gal4 DBD-hGR LBD construct in the cell-based 
assay is its ability to traffic to the nucleus.  Like many other activator proteins, hGR binds 
to a masking protein in the absence of a cellular signal.  In the presence of its ligand 






















dexamethasone, the hGR LBD is released from Hsp90 and trafficked to the nucleus.10,11  
This assures nuclear localization of our isoxazolidine AD upon binding its target.  
Although this is advantageous for the discovery of ADs, it circumvents an important 
consideration in activator artificial transcription factor (ATF) design.  The creation of 
“drug-like” activator ATFs will require not only a small molecule AD, but also a small 
molecule DBD. 
 One class of small molecule DBDs which have shown promise as activator ATFs 
when conjugated to appropriate ADs are the polyamides developed by Dervan.1,12-14  
These DBDs were originally inspired from the DNA binding natural product distamycin.  
Through the use of pyrrole and imidazole groups on a polyamide backbone, these 
molecules are capable of recognizing each of the four base pair combinations (A-T, T-A, 
G-C, and C-G).15  In order to determine if a polyamide conjugated isoxazolidine would 
activate transcription in cell culture, Sara Buhrlage coupled the amphipathic 
isoxazolidine to the polyamide ImPy7 and I constructed a reporter plasmid with 
appropriate binding sites.  This particular polyamide binds to double stranded DNA with 





Figure IV-10: Conjugate of polyamide (ImPy7) with the amphipathic isoxazolidine.  
This polyamide (ImPy7) binds to the DNA sequence WGWWWW where W represents A 
or T. 
 
 We expected to see a decrease in the activity of the isoxazolidine in this context 
for several reasons.  First, the lack of DNA sequence specificity of this particular 
polyamide likely results in a substantial amount of binding to other sequences of DNA.  
Further, the polyamide binds its DNA sequence with much less affinity than the Gal4 
protein DBD (about 100-fold weaker), resulting in the need for a higher concentration in 
the nucleus.  The last major difference involves permeability of the molecule.  The 
OxDex steroid is an extremely cell permeable compound and upon binding to its protein 
target is trafficked directly to the nucleus.  The polyamide on the other hand has much 
lower permeability and requires transport across not only the cell membrane, but also the 
nuclear envelope.  For example, the Kodadek peptoid which demonstrated nearly 900-
fold activation in the two-hybrid assay showed only five-fold activity when coupled to a 
polyamide.14 
 For this experiment, HeLa cells were cotransfected with a plasmid containing 
either six or zero polyamide binding sites upstream of a firefly luciferase gene and the 
same Renilla transfection control as earlier described.  The polyamide-isoxazolidine 
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conjugate was added as a DMSO solution at various concentrations resulting in a final 
DMSO concentration of 1% (vol/vol).  The fold activities were determined by dividing 
the luciferase activity at each concentration by that measured for cells incubated with a 

























Figure IV-11: The completely synthetic activator ATF IV-5 activates transcription in 
HeLa cells. 
 
 Consistent with our predictions, higher concentrations of IV-5 were needed in 
order to observe activation as compared to the two-hybrid assay.  Additionally, the fold-
activation at the highest concentration is reduces (3.5-fold vs. 80-fold).  Although this 
experiment needs to be repeated at higher concentrations to assess the EC50, this is an 
extremely exciting initial result.  This represented the first completely synthetic activator 
ATF composed of both a small molecule DBD and AD which demonstrated activity in 
living cells.  It is likely that factors such as linker length and choice of polyamide DBD 
will result in more active constructs.  Although much more work needs to be carried out 
on the polyamide-isoxazolidine, this represents the most “drug-like” activator ATF 
described and an enormous step towards the development of transcription-based 
therapeutics. 
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E. Insights into Cellular Mechanism of the Isoxazolidine ADs 
 All of the experiments thus far are consistent with the isoxazolidines functioning 
in a similar manner as endogenous ADs.  We have demonstrated that the isoxazolidine 
AD and DBD act in an independent manner (Chapter III + IV), amphipathic 
characteristics are critical for activation (Chapter III + IV), and specific presentation of 
functionality is not required for function (Chapter III).  This would suggest that the 
isoxazolidines also target similar surfaces as endogenous activators.  In order to address 
this question, a series of inhibition experiments were performed in yeast and mammalian 
cells. 
 Since activator proteins target a limited number of coactivator binding surfaces, it 
is possible to completely titrate these sites and thus prevent recruitment of the 
holoenzyme by DNA-bound activators.  This phenomenon, named squelching, was first 
recognized by Ptashne in an experiment with the potent activator Gal4.16  They found that 
promoters bearing Gal4 binding sites were inhibited when Gal4 was overexpressed.  This 
can be taken one step further to determine if different activators target the same 
coactivator binding sites.  A cross interference experiment involves expressing or titrating 
free AD and observing the effect it has on a second DNA-bound activator.  If the two 
ADs target the same set of protein surfaces, inhibition will likely be observed.  
Conversely, if they target different sites, transcription should remain unaffected.17 
 In order to determine if the small molecules are indeed targeting similar surfaces 
as endogenous ADs, I performed a series of cross interference experiments.  The well 
studied amphipathic ADs of GCN4, Gal4, and VP16 were tested.  Towards this end, 
Jenifer Lum cloned GCN4(107-144), Gal4(840-881), and VP2 (a peptide derived from 
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the VP16 AD) into plasmids as fusions with the DBD of Gal4 (residues 1-100).  Each of 
these vectors was transformed into LS41 yeast, a strain bearing a β-galactosidase reporter 
with a promoter containing Gal4 binding sites, and plated on selective agar plates.  
Colonies were then chosen and grown in liquid media in preparation for a quantitative β-
galactosidase assay.  The next day, all yeast cultures were diluted to a density of 7 X 106 
(cells / mL) as determined with the OD660.  IV-6 was then added as a DMSO solution to a 
final concentration of 10 and 100 µM.  Following a16 hr incubation at 30ºC the β-
galactosidase activity was measured (Figure IV-12). 
 
Figure IV-12: Cross interference experiments between IV-6 and various amphipathic 
ADs.  
 
In addition to these experiments, two more controls were performed.  The first involved 
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13a).  If inhibition were observed in this context, we could conclude IV-6 disrupts basal 
transcription.  The second control involved the use of an isoxazolidine we would not 
expect to function as an activator due to its polarity (IV-7) (Figure IV-13b).   
 
Figure IV-13: a) Inhibition of basal transcription was not observed with the addition of 
IV-4.  b) The polar isoxazolidine (IV-7) does not interfere with VP2 dependent 
activation. 
 
As demonstrated in Figure IV-12, the amphipathic isoxazolidine IV-6 interferes with 
activation by VP2, decreasing transcriptional activation by about 50% at 100 µM, but not 
that of GCN4 or Gal4.  The fact that the similar effects are observed for both GCN4 and 
Gal4 is not surprising since cross linking experiments have suggested they target four of 
the same protein complexes (Mediator, SAGA, NuA4, and TFIID) through three proteins 
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interactions in addition to the complex TFIIB.20  At least two possible models exist to 
explain the cross interference data.  One possibility is that the isoxazolidine specifically 
target TFIIB, a complex not essential for activation by Gal4 or GCN4.  A second 
possibility is that the affinity of the Gal4 and GCN4 ADs for their protein targets is much 
stronger than that of VP2 for identical targets.  Distinguishing between these two models 
is challenging with the data I have described, although I feel it is unlikely the 
isoxazolidines target a single protein complex, considering the promiscuous binding 
profile observed with endogenous activators and is likely recapitulated with the 
isoxazolidine.  For example, recent NMR experiments performed by Sara Buhrlage 
suggest a specific interaction between the isoxazolidines and the KIX domain of CBP, 
consistent with the small molecule binding several targets.  In order to more fully 
characterize the interactions made by the isoxazolidines, cross-linking experiments could 
be performed with the small molecule in the context of transcriptional activation, a 
project currently under investigation in my lab. 
 Presumably, the amphipathic isoxazolidine targets similar protein surfaces in both 
yeast and mammalian cells.  In order to investigate this, a similar cross interference 
experiment was performed in HeLa cells.  This was accomplished with the cotransfection 
of HeLa cells with three plasmids.  The first encoded Gal4(1-147)-VP2, the second 
contained Gal4 binding sites upstream of a luciferase reporter gene, and the third was the 
Renilla transfection control.  Following the transfection, IV-6 was added with a final 
concentration of 10 and 100 µM.  The cells were incubated for 48 hours prior to 
measuring the luciferase activity (Figure IV-14). 
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Figure IV-14: Activation of transcription by VP2 in HeLa cells is inhibited by the 
addition of IV-6. 
 
As expected, similar inhibition was observed in mammalian cells as previously seen in 
yeast.  This demonstrates that the amphipathic isoxazolidine likely targets similar 
proteins in yeast as mammalian cells. 
 In summary, the amphipathic isoxazolidine represents the first small molecule 
activation domain with activity in living cells.  Furthermore, initial studies indicate 
function when conjugated to a polyamide DBD, representing an entirely small molecule 
activator ATF.  All studies thus far are consistent with a model in which the amphipathic 
isoxazolidine targets similar surfaces as endogenous ADs.  Through these interactions, 
the small molecule appears to recruit proteins and protein complexes to DNA and assist 
in the formation of the pre-initiation complex, the first mechanistic step in eukaryotic 
transcription.  Although many questions about these small molecule ADs are currently 
being addressed by numerous graduate students in my lab (some of which are the focus 




















F.  Experimental Details 
Yeast Cell Based Assay 
 V784Y yeast, provided by Dr. Virginia Cornish, Columbia University, was plated 
on U-H- SC agar plates.  Individual colonies were chosen and grown overnight (~16 
hours) in U-H- SC media supplemented with 2% raffinose at 30°C.  The following day 
the cell density was determined by OD660 measured on a Carey UV-Vis.  The cells were 
then diluted to give a final concentration of 7 X 106 cells/mL in U-H- SC media 
supplemented with 2% raffinose and 2% galactose in a volume of 3 mL.  The compounds 
were then added to the cells as methanol solutions to a final concentration of 1 µM.  All 
concentrations of methotrexate tagged compounds were determined with the 
characteristic UV-vis absorption of methotrexate at λmax = 257, 302, and 370 nm with 
extinction coefficients of 23,000, 22,000, and 7,100 M-1cm-1.  The cells were grown 
overnight (~16 hours) and the following day a b-galactosidase assay was performed as 
described in Chapter II. 
 
Hela Cell Assay 
 HeLa cells (CCL-2) were purchased from the American Type Culture Center 
(ATCC) and upon arrival immediately plated onto a treated polystyrene Petri dish 
(Corning) with 10 mL of D-MEM supplemented with 10% FBS, NEAA, and PSG 
(Invitrogen).  Following a 2 hour incubation to allow the cells to adhere, the media was 
replaced with fresh D-MEM.  Cells were then grown at 37°C and 5% CO2 to 
approximately 80% confluence. 
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 Upon reaching the desired confluence, the D-MEM was removed from the cells 
and 2 mL of 0.25% trypisin added.  The cells were incubated with the trypisin solution 
for 10 minutes at 37°C and 5% CO2.  Following the incubation D-MEM was added to the 
cells in order to remove them from the plate.  The solution of media and cells were then 
centrifuged at 1000 RPM for 1 minute.  The supernatant was removed and the cells were 
resuspended in fresh D-MEM. 
 The concentration of the cells was calculated using a Hausser Scientific improved 
Neubauer phase counting chamber hemocytometer.  Based on the determined 
concentration, the cells were diluted to 150,000 cells/mL with the addition of more D-
MEM.  100 mL of the diluted cell solution were then added to each well of a flat-bottom 
96-well plate.  The plated cells were incubated overnight (~16 hours) at 37°C and 5% 
CO2. 
 The media was removed from the plated cells and they were washed once with 
Opti-MEM and then transfected.  The transfection procedure consisted of mixing 50 ng 
of pCMV-GG (provided by Tom Kodadek), 50 ng pG5 (Promega), and 1 ng of pRLSV40 
(Promega) in 50 µL of Opti-MEM for each well to be transfected.  A second solution of 
0.3 µL of Lipofectamine 2000 (Invitrogen) per well was diluted in 50 µL of Opti-MEM.  
After 15 minutes of incubation at room temperature, the two solutions were combined 
and allowed to incubate for another 15 minutes at room temperature.  100 µL of the 
combined plasmid Lipofectamine 2000 solution was then added to each well and the cells 
were incubated for 3 hours at 37°C and 5% CO2. 
 The plasmids from the transfection served the following purposes.  The pCMV-
GG served as the expression vector, which expressed Gal4(1-147)-hGR(499-777) under 
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the control of the CMV promoter in order to localize the small molecules to DNA.  The 
pG5 plasmid served as the reporter vector containing five Gal4 binding sites upstream of 
a Firefly luciferase reporter gene.  The pRLSV40 served as a transfection control and 
expressed Renilla luciferase on a constitutively active SV40 promoter. 
 At the end of the three hour incubation, the transfection solution was removed and 
replaced with 100 mL D-MEM (+FBS +NEAA).  To this media was added 1 µL of either 
DMSO or an appropriate concentration of one of the OxDex conjugated compounds.   
The cells were then incubated for 40 hours at 37°C and 5% CO2. 
 Following the 40 hour incubation, the media was removed from each well of cells 
and replaced with 20 mL of passive lysis buffer (Promega).  The cells were lysed by 
shaking at room temperature in the lysis buffer for 15 minutes.  The dual luciferase assay 
was then performed using the Promega Dual-Luciferase Assay kit.  The luminescence 
from each sample was measured on a Berthold B12 single cuvette luminometer. 
 
Polyamide Activation Assay 
 This assay was carried out in the same manner as the HeLa cell assay with a few 
variations.  The pTKGG plasmid was not used, since the DBD in this case was attached 
directly to the AD.  Additionally, the pG5 plasmid was replaced with pE1b (a plasmid 
containing Firefly luciferase under the control of the E1b promoter) or pE1b-HPBX6 (a 
plasmid containing the Firefly luciferase reporter under the control of the E1b promoter 





 Both plasmids used in the polyamide activation assay were constructed from 
pGL3-Basic vector containing the Firefly luciferase gene.  Primers (5’-GA TCT TAG 
AGG GTA TAT AAT GGA TCA-3’) and (5’-AG CTT GAT CCA TTA TAT ACC CTC 
TAA-3’) were annealed and inserted into BglII/HindIII cleaved pGL-3 Basic vector to 
construct pE1b, which has an E1b promoter in front of Firefly luciferase.  Primers (5’-
CTAGC ATA ACA TTC CAT ATG TTA TAC ATA ACA TTC CAT ATG TTA TAC 
ATA ACA TTC CAT ATG TTA TAC A-3’) and (5’-GATCT GTA TAA CAT ATG 
GAA TGT TAT GTA TAA CAT ATG GAA TGT TAT GTA TAA CAT ATG GAA 
TGT TAT G-3’) were annealed and inserted into NheI/BglII cleaved pE1b vector to 
make pE1bHPBX6.  The underlined residues in the oligo represent the polyamide 
binding sites.  All plasmids were amplified in DH5α E. coli and sequenced at the 
University of Michigan sequencing core. 
 
Inhibition Assays 
 The yeast inhibition assays were performed in LS41, a strain a β-galactosidase 
reporter gene downstream of five Gal4 binding sites (provided from Dr. Aseem Ansari, 
University of Wisconsin).  The plasmids expressing the Gal4 fusion proteins were 
constructed by Jenifer Lum.  LS41 was transformed with plasmids which expressed 
Gal4(1-100)-Gal4(840-881), Gal4(1-100)-GCN4(107-144), or Gal4(1-100)-VP2 and 
plated on selective plates.  Individual colonies were chosen and grown in U-H- SC media 
supplemented with 2% raffinose.  The following day, the cells were diluted to 7 X 106 
 96 
cells/mL and IV-6 was added in DMSO resulting in a final concentration of 10 and 100 
µM.  The following day β-galactosidase assays were performed as previously described. 
 The HeLa cell inhibition assay was performed nearly identical as earlier described 
except the commercial plasmid pM-VP2 was used in place of pTKGG.  This plasmid 
expressed Gal4(1-147)-VP2. 
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 Although a significant amount of progress has been made in the development of 
the isoxazolidine AD, several questions are currently under investigation.  The 
amphipathic isoxazolidine (IV-1) is unlikely to be the sole small molecule AD with 
activity.  Changes in hydrophobicity and electronics of the side chain functionality will 
likely produce small molecules with varied potency which can be used to regulate 
transcription to desired levels.  Although potent activators can often regulate transcription 
500-fold or more in cells, this level is not necessarily needed to be physiologically 
relevant.  For example, a genome wide expression analysis of a various lung tumor cells 
demonstrated up- and down-regulation of most genes around five fold, levels likely 
achievable from our small molecule ADs.1  Derivatives of IV-1 will give greater insight 
into the mode of action of the isoxazolidines.  Specifically, the incorporation of cross-
linking agents onto the scaffold will elucidate direct cellular targets of this class of 
activators.  Other areas to address involve the use of different DBD as well as testing the 






A. Other Isoxazolidine ADs 
 In order to determine features of the isoxazolidines that are important for activity, 
I have tested other derivatives recently synthesized by my co-workers, although a 
complete SAR analysis has not been completed.  One region of the small molecule which 
can be derivatized with relative ease is the group attached to N2 of the isoxazolidine ring.  
I have found that changes in the N2 benzyl group have a dramatic effect on the overall 
potency of the AD in a cellular context (Figure V-1).  For instance, conversion to a 
biphenyl or para-trifluoromethyl completely abrogates activity in cells.  On the other 
hand, the napthyl derivative is still active, although at significantly attenuated levels.  
While these structural changes could have an effect on the cell permeability thereby 
decreasing activity, it seems more likely that the benzyl group at this position is 
important for target interactions.  These are just a few of the derivative we would like to 
















































































































Figure V-1: Cellular activity of derivatives of the amphipathic isoxazolidines. 
Supporting this model are NMR structural studies by my co-worker Sara Buhrlage of the 
amphipathic isoxazolidine in complex with the coactivator CBP.  Upon interaction with 
CBP, the benzyl resonances shift significantly.  However, additional data is required to 
draw firm conclusions and future experiments examining a wider range of substitution at 






B. Cross-linking studies 
 The cross interference experiments descried in Chapter IV provide some 
information into possible cellular targets of the isoxazolidine, but cross-linking of the 
isoxazolidine in cell culture will result in more direct evidence.  Towards this end, a 
graduate student in my lab (Caleb Bates) has been working on the synthesis of a 
benzophenone derivative of the isoxazolidine AD (Figure V-2). 
 
Figure V-2: A proposed isoxazolidine with a cross-linking agent attached to N3 in order 
to determine cellular targets. 
 
Upon irradiation of this compound, the benzophenone moiety will cross-link proteins in 
close spatial proximity.2  One possible complication involves the derivatization of the 
N3-benzyl group.  As mentioned, this can have a negative impact on activity and could 
possibly prevent binding of V-4 to its targets within the transcriptional machinery.  If this 
ends up the case, the cross-linking moiety could be placed in other positions as to prevent 
interference of activation.  A better understanding of the specific binding sites of the 












C. Variation in the DBD 
 The modular nature of transcriptional activators should allow for the 
incorporation of numerous different DBDs onto our isoxazolidine AD, allowing for a 
variety of mechanistic studies.  This modular nature has been demonstrated in my recent 
work involving the polyamide DBD, however other choices might prove more successful.  
The low specificity and stability of the polyamide small molecule DBDs make them less 
attractive as a long term strategy.  As described in Chapter I, another possibility is the use 
of triplex forming oligonucleotides (TFOs).  These molecules are highly specific and 
stable both in cell culture and in vivo.  A graduate student in my research lab (Gayle 
Gawlik) is currently investigating the utility of this DBD in the context of our 
isoxazolidine AD.   
 
D. Activation of Transcription in vivo 
 Perhaps the most exciting future direction of this work involves the use of the 
isoxazolidine ADs in a mouse animal model.  The first stage of this work involves 
creating a stably transfected cell line containing both the expression vector (Gal4-DBD 
hGR-LBD) as well as a luciferase reporter vector.  Following the stable transfection, the 
HeLa cells can be xenografted into mice.  If the small molecules can activate in this 
context, we would expect to see up-regulation of the luciferase reporter upon intra-
peritoneal injection of the OxDex conjugated isoxazolidine.  Remarkably, imaging 
technology allows for the visualization of the luciferase without the need for sacrificing 
the animals.  Towards this end, we have begun a collaboration with another research 
group at the University of Michigan Cancer Center, the facility in which the testing will 
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take place.  The observation of activity in a living biological system would be a 
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